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Abstract 
 
 
Expression of uPAR has been extensively correlated with the malignant progression and 
metastasis of cancer; however, little evidence for a causal connection between increased 
uPAR expression and these processes has been documented to date. A complete 
functional alanine scan of human uPAR, pinpointed the extracellular matrix protein 
vitronectin (VN) as the critical uPAR-interactor required to induce cell adhesion, 
migration, and signaling in vitro, identifying this molecular interaction as a possible 
target for anti-cancer therapy (Madsen et al., 2007).  
The same study helped to determine the binding epitope in uPAR responsible for 
its interaction to VN in an integrin-independent fashion. The composite epitope is fully 
conserved in mouse and included three amino acids (W32, R58, I63) in domain 1 (D1) 
and 2 amino acids (R92, Y93) in the linker region between D1 and D2. 
We substituted these residues with alanine by site directed mutagenesis and 
analyzed the biological activity of resulting receptor variants in CHO Flp-In cells as 
compared to wild-type muPAR.  
All the mutant receptors displayed a deficiency for the binding to VN, 
preserving the receptor binding to its natural ligand uPA. They also failed to induce 
muPAR-induced cell morphology changes. These changes include the formation of 
actin-rich lamellipodia, loss of stress fibers, reduced cell-cell contact as well as a 
complete failure to form colonies when seeded at low density. The mouse uPARW32A 
(muPARW32A) was chosen for further experiments since it did not show folding 
problems. Moreover the W32 position is not a part of the receptor chemotactic epitope 
and is not involved in the receptor cleavage. 
Additional experiments using recombinant soluble muPAR confirmed the impaired VN-
binding and a normal uPA-binding. 
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To determine if uPAR and/or VN are involved in tumor formation and 
progression, and more specifically, if the direct uPAR/VN-interaction is important in 
this process, we exploited a xenograft mouse model. For this purpose muPAR or 
muPARW32A or a muPAR variant lacking of the D1, required for both VN and uPA 
binding (muPARΔD1), were expressed in HEK293 Flp-In GFP positive cells and injected 
in the fourth mammary fat pad of immunodeficient mice. 
In parallel the cells were tested for some in vitro assays. We demonstrated that 
HEK293 cells expressing muPAR are more proliferating and less apoptotic than the 
other cells. The interaction with VN is required to increased cell proliferation and to 
prevent from apoptosis. Moreover, muPAR-VN interaction induced cell spreading and 
migration. 
muPAR expressing cells formed palpable tumors earlier than cells expressing 
the mutant receptors and the tumor growth was significantly faster. Despite the 
expression of the muPARW32A didn’t affect the timing of the primary tumor formation, 
it drastically slowed down the growth of the primary tumor mass.  
Finally we conducted in vitro studies to determine the molecular mechanisms 
underlying the possible role of the uPAR/VN-interaction in vivo. From these tests 
emerged that VN may act as an adhesion “bridge” between different cells expressing 
uPAR and VN-integrins or cells expressing both uPAR, suggesting a possible role of 
the uPAR/VN-interaction not only in cell-ECM interactions but also in cell-cell 
adhesion events including the extravasation of metastatic cancer cells. 
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 Introduction 
 
 
A fundamental property of living systems is to respond to external stimuli. The 
extracellular matrix (ECM) provides signaling cues that regulate cell behavior and 
orchestrate functions of cells in tissue formation and homeostasis. The ECM is the 
defining feature of connective tissue and includes the interstitial matrix, found in the 
intercellular spaces among various cells, and the basement membrane. The interstitial 
space consists of protein fibers embedded in an amorphous mixture of huge 
proteoglycan molecules and acts as a compression buffer against the stress placed on the 
ECM. Basement membranes are sheet-like depositions of ECM on which various 
epithelial cells rest.  
Many cell types contribute to the production of the various ECM components 
thus determine the properties of the connective tissue. The majority of these 
components are produced by resident cells and secreted into the ECM via exocytosis. 
Due to its diverse nature and composition, the ECM can serve many functions, such as 
providing support and anchorage for cells, segregating tissues from one another, and 
regulating intercellular communication. In addition, it sequesters a wide range of 
cellular growth factors, and acts as a local reservoir for them.  
The normal formation and function of multicellular tissues require correct 
expression and function of genes that control interactions of cells with the ECM. 
Misregulation of cell–ECM interactions can contribute to many diseases, including 
developmental, immune, haemostasis, degenerative and malignant disorders. The role of 
the ECM in cancer is a long-standing topic of investigation. In the ECM, there appears 
to be a proteolytic cascade that is involved in clearance of molecules from the ECM, 
interstitial fluid dynamics and turnover of individual ECM components as well as 
remodeling of tissue. This remodeling process is also critical in tumor invasion, for the 
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creation of space for cellular growth, and in metastasis formation, that often involves 
the destruction of extracellular matrix. 
The urokinase-type plasminogen activator receptor (uPAR), first cloned in 1985, 
through the binding of urokinase plasminogen activator (uPA) guides the conversion of 
plasminogen into the active serine-protease plasmin at the leading edge of cells. For this 
reason, it was initially believed that the primary function of uPAR at the leading edge of 
migrating cells was to regulate invasive cell migration by virtue of its ability to promote 
degradation of the ECM. Indeed uPAR has been detected in invadopodia (Artym et al., 
2002) and in the invasive front of many human tumors (Dano et al., 2005; Nielsen et al., 
2007) and its expression on tumor cells strongly correlates with their migratory and 
invasive phenotype (Wang, 2001). However, it is becoming evident that uPAR also 
elicits a plethora of non-proteolytic functions, and its involvement in cell proliferation 
and migration is now well documented (Blasi and Carmeliet, 2002).   
 
 
Aim of the work 
 
 
In this thesis I will investigate the importance of the interaction of uPAR and VN, an 
ECM component, in a xenograft mouse model of tumorigenesis. In the view of that the 
VN-binding site of mouse uPAR will be investigated to better understand uPAR-VN 
interaction and to further produce a mutant muPAR receptor having an impaired VN-
binding site.  
In vitro experiments will be also conducted to understand how uPAR-VN 
interaction can occur in vivo and what can be the in vivo relevance of their binding. 
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Urokinase-type plasminogen activator receptor (uPAR) 
 
uPAR expression  
uPAR is a glycosyl-phosphatidylinositol (GPI)-anchored cell surface receptor expressed 
by many different tissues and cell types including epithelial (Limongi et al., 1995), 
keratinocytes (Romer et al., 1994), endothelial (Pepper et al., 1993), fibroblasts 
(Anichini et al., 1994), megakaryocytes (Wohn et al., 1997), podocytes (Wei et al., 
2008), placental trophoblasts (Pierleoni et al., 1998) and most haematopoietic cells 
counting; peripheral monocytes/macrophages (Miles and Plow, 1987; Nykjaer et al., 
1990), neutrophils (Plesner et al., 1994a), granulocytes (Miles and Plow, 1987), natural 
killer cells (Nykjaer et al., 1992), activated T-lymphocytes (Nykjaer et al., 1994) as well 
as osteoblasts and osteoclasts (Daci et al., 1999; Rabbani et al., 1997). Under normal 
physiological conditions basal expression levels of uPAR are rather low in all the 
various homeostatic mouse tissues that have been examined. However, uPAR 
expression is upregulated during certain tissue remodeling processes (Romer et al., 
1994; Solberg et al., 2001), in host response to infection (Coleman et al., 2001; Speth et 
al., 1998), during inflammation and in many human diseases, including, Alzheimer’s 
disease (Walker et al., 2002), rheumatoid arthritis (Del Rosso et al., 1999), multiple 
sclerosis (Balabanov et al., 2001), atherosclerosis (Okada et al., 1998) and cancer. 
uPAR is over-expressed in numerous human tumors, including leukemias (Lanza et al., 
1998; Mustjoki et al., 1999; Plesner et al., 1994b), breast (Carriero et al., 1997), lung 
(Morita et al., 1998), bladder (Hudson and McReynolds, 1997), colon (Pyke et al., 
1991), liver (De Petro et al., 1998), pleura (Shetty and Idell, 1998b), pancreas 
(Taniguchi et al., 1998) and brain (Yamamoto et al., 1994). Its expression levels 
correlated with poor prognosis and an unfavorable outcome, due to the increased risk of 
tumor recurrence and metastatic formations in patients (Ganesh et al., 1994; Grondahl-
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Hansen et al., 1995; Pedersen et al., 1994; Sidenius and Blasi, 2003; Stephens et al., 
1999).  
 
uPAR gene 
The human uPAR gene, located to chromosome 19q13.2 (Borglum et al., 1992), is 
made of seven exons separated by six introns and occupies about 21.23 kb (Wang et al., 
1995). The seven exons of the gene are 101-, 111-, 144-, 162-, 135-, 147- and 563 bp 
long, respectively and encode 19, 37, 48, 54, 45, 49 and 83 amino acids residues, 
respectively. Exons 2+3 encode domain I, 4+5 encode D2, while exons 6+7 encodes for 
D3. Each domain is separated from the next by an intron. Part of the exon 1 encodes 
most of the hydrophobic leader sequence whereas the hydrophobic sequence necessary 
for GPI-anchor attachment is encoded in exon 7 (Roldan et al., 1990). 
The six introns of the uPAR gene are approximately 2.04, 2.62, 8.42, 0.906, 3.10 
and 2.78 kb long, respectively. They begin with GT and end in AG. The proximal 
promoter region of the uPAR gene lacks conventional TATA and CAAT boxes but 
contains a CpG-rich island and several putative cis-regulatory elements (AP1, AP2, SP1 
and NF-κB) (Fig.1). Primer extension experiments demonstrated that the transcription 
start site is located at 50 bp upstream of the translation site (ATG) of the human gene 
(Wang et al., 1995). 
Promoter analyses in transgenic mice have shown that uPAR expression in 
different tissues is controlled at a transcriptional level (Wang et al., 2003). Cytokines 
such as TNF-α or TGF-β and phorbol esters stimulate transcription (Lund et al., 1995; 
Lund et al., 1991a; Lund et al., 1991b; Niiya et al., 1998; Picone et al., 1989; Wang et 
al., 1994), while mRNA binding proteins regulates the stability of the uPAR mRNA 
(Lund et al., 1995; Lund et al., 1991a; Niiya et al., 1998; Shetty and Idell, 1998a; Shetty 
et al., 1997; Wang et al., 1998). In addition tumor-specific transcription factors have 
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been documented to bind the promoter in gastrointestinal cancer (Schewe et al., 2003). 
The uPAR mRNA stability is partly regulated by the phosphoglycerate kinase (PGK), 
which recognizes a short fragment within the uPAR coding region (Shetty et al., 2004). 
Despite the expression of uPAR during early embryogenesis, it is surprising that gene 
targeting of uPAR in mice is compatible with normal development and fertility (Bugge 
et al., 1995). 
The uPAR cDNAs from other species including mouse (Kristensen et al., 1991), 
bovine (Reuning et al., 1993) and rat (Rabbani et al., 1994) have been also isolated and 
found to have similar sequence coding for the three domains of uPAR. The interspecies 
conservation of the individual domains is more than 60% (Kratzschmar et al., 1993). 
 
 
 
Figure 1: Nucleotide sequence of the human uPAR gene.  
 
The complete amino acid sequence (single letter code) is shown above the first nucleotide of each codon. 
Exons are designated by upper-case and bold face letters and introns designated by lower-case letters. The 
 13 
5’-flanking region and the 3’end sequence obtained from genomic clones are indicated by italics. The 
sequence is numbered and the translation-start site of known cDNA is considered as position 1. The 
beginning and the end of each intron and the putative transcription-factor-binding sites are underlined. 
The poly(A) attachment site is indicated by an arrowhead. Figure taken from (Wang et al., 1995). 
 
 
uPAR protein 
The nascent uPAR is translated as a 313 amino acids polypeptide, preceded by a 22 
amino acid signal peptide. This signal peptide together with a C-terminal GPI-anchoring 
peptide (30 residues) are excised from the nascent protein during posttranslational 
processing, generating a 283 amino acid single chain polypeptide, linked to the outer 
membrane leaflet by a GPI-anchor (Moller et al., 1992; Ploug et al., 1991). The fact that 
uPAR is tethered to the cell surface by a glycolipid renders it predisposed for cleavage 
by phospholipases (Ploug et al., 1991; Wilhelm et al., 1999) and soluble uPAR (suPAR) 
has been observed in vitro as well as in vivo (Pedersen et al., 1993). This process is 
called uPAR shedding. Full-length suPAR binds uPA at an indistinguishable affinity 
from GPI-anchored full-length uPAR (Ploug et al., 1994). The mature uPAR protein is a 
single-chain protein of 55-60 kDA. It consists of three homologous domains, determed 
DI (residues 1-87), D2 (residues 88-191) and D3 (residues 192-283). The first domain 
contains the major binding region to uPAR natural ligand uPA (Huai et al., 2006) and is 
also required for uPAR-mediated cell binding to VN (Sidenius and Blasi, 2000). The 
other two domains have no detectable uPA binding activity. However, they might be 
important for high affinity uPA-binding as the purified first domain has a 1,500-fold 
lower ligand affinity than the original three-domain uPAR (Ploug et al., 1994; Riittinen 
et al., 1996). 
The mature uPAR protein is highly glycosylated and decreases to Mr of 35 kDa 
upon deglycosylation (Behrendt et al., 1990; Nielsen et al., 1988). The N-linked 
glycosylation profile is highly heterogeneous and dependent on cell type and 
differentiation state (Behrendt et al., 1990; Lund et al., 1995). According to the sequence 
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it is predicted that human uPAR has five N-linked glycosylation sites (Asn52, Asn162, 
Asn172, Asn200 and Asn233) (Roldan et al., 1990). However, studies using recombinant 
uPAR (1-277) produced and secreted by CHO cells, demonstrated that only the first four 
of these sites are actually being glycosylated (Ploug et al., 1998). Interestingly these 
glycosylation sites exhibit site-specific heterogeneity (Ploug et al., 1998).  
 
Relationship between uPAR and the Ly-6 gene family  
Protein database searching using the consensus sequence of the putative 
domains of uPAR revealed homology to a diverse group of single domain glycoproteins 
(Behrendt et al., 1991). This group includes a gene family of murine leukocyte antigens 
collectively known as Ly-6 and the human regulatory complement component CD59. 
Like uPAR these are all glycolipid-anchored membrane proteins and have gene 
organization comparable to those segments of the uPAR gene encoding the individual 
domains (Ploug and Ellis, 1994). Moreover uPAR, Ly-6 and CD59 genes show a 
similar three-dimensional folding motif. The biological significance of the similarity 
between uPAR and members of the Ly-6 family genes is not clear at present. 
 
uPAR  structure 
The crystal structure of soluble uPAR (suPAR) was first solved in association with a 
competitive inhibitor (AE147) of the uPA-uPAR interaction (suPAR/AE147) (Llinas et 
al., 2005).  The structure of uPAR bound to the catalytic inactive amino-terminal 
fragment of uPA (ATF) was solved later on, first in a ternary complex 
(ATF/suPAR/ATN615), where ATF was bound to uPAR using a Fab fragment of the 
monoclonal antibody (ATN615) binding domain III of uPAR (Huai et al., 2006) and 
then in a binary complex (ATF/suPAR), where suPAR was bound directly to the ATF 
of uPA (Barinka et al., 2006).  Finally the crystal structure of uPAR in complex with 
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both ATF and the SMB domain of VN was determined (suPAR-ATF-SMB) (Huai et 
al., 2008). 
The solved crystal structure revealed that the uPAR three domains adopt a 
typical three-finger fold with three adjacent loops rich in β-pleated sheets and a small 
C-terminal loop. The secondary structure of each domain is composed by three 
consecutive β-sheets; D1 and D2 having six β-strands and D3 having five β-strands 
(Fig. 2). Altogether, uPAR possesses 17 antiparallel β-strands and 3 short helical 
stretches at the edge of loop 3 of D3. This fold possesses four disulphide bonds in D1 
and five disulphide bonds in D2 and D3. The three domains of uPAR are assembled in a 
circular manner generating an almost globular receptor with a breach between D1 and 
D3. This topology creates a central cavity (19 Å deep) that accommodates uPA; the top 
of the cavity is widely open (21-25 Å large) while gradually tightening towards the 
bottom. This characteristic shape of the uPAR complex creates a large external surface 
containing the interdomain linker regions and the five N-glycosylation sites, permitting 
interactions with other proteins, such as vitronectin (Wei et al., 1994), or even 
oligomerization of the uPAR molecule (Cunningham et al., 2003). 
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Figure 2: uPAR structure. 
 
Domain structure of suPAR in the ATF/suPAR/ATN615 complex. The D1 domain (orange, residues 1 to 
80) contains six β strands (β1, residues 2 to 7; β2, 10 to 16; β3, 23 to 32; β4, 38 to 46; β5, 53 to 58; β6, 63 
to 71). The D2 domain (magenta, residues 93 to 191) contains six β strands (β7, 94 to 99; β8, 111 to 114; 
β9, 121 to 128; β10, 143 to 149; β11, 156 to 161; β12, 164 to 171) and a short α helix (α1, 104 to 107). 
The D3 domain (green, residues 192 to 283) contains five β strands (β13, 193 to 198; β14, 211 to 214; 
β15, 220 to 226; β16, 237 to 242; β17, 262 to 266) and two short α helices (α2, 244 to 246 and α3, 253 to 
256). Disulfide bonds are shown in dashed lines (blue). The disordered loops are connected by the dash 
line colored as is the backbone to which they belong. Copy taken from the published crystal structure of 
the ATF/suPAR/ATN615 complex (Huai et al., 2006).  
 
Important for the globular conformation of uPAR are the non-covalent interfaces 
between the three domains (interdomain interfaces). The interdomain interfaces provide 
flexibility to the structure and are greatly affected upon uPA binding (Huai et al., 2006).  
The aperture of the D3-D1 interdomain interface (476 Å2) is brought together by 
three hydrogen bonds between these two domains (His47-Asn259, Lys50-Asp254, and 
Arg53-Asp254) (Huai et al., 2006). Interestingly these three hydrogen bonds are not 
observed in the D3-D1 interface of suPAR/AE147 complex indicating that the binding 
of ATF invokes closure of the bowl-like structure by eliciting changes of the individual 
domains. This is supported by the larger D3-D1 interface observed upon ATF binding 
(476 Å2 vs. 169 Å2).  In the ATF/suPAR/ATN615 complex the angle between D1 and 
D2 is reduced by 20° due to conformational shift (9.5Å) centered on the 
corresponding interdomain β-strands (Huai et al., 2006). Another alteration observed 
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upon ATF binding was found in the connecting linker region (residues 78-92) between 
D1 and D2 (Barinka et al., 2006). Upon the binding of ATF this linker region is 
immobilized in its open conformation distanced by more than 14 Å from the receptor 
body, as observed in the binary ATF/suPAR complex. The immobilization of the 
flexible linker region is interesting as this stretch of residues is susceptible to proteolytic 
cleavage by various proteases including uPA, plasmin, elastase, cathepsin G and pro-
matrix metalloproteases (MMPs) (Andolfo et al., 2002; Beaufort et al., 2004; Hoyer-
Hansen et al., 1997). The physiological outcome upon cleavage includes loss of D1, 
deficient uPA -and VN binding (Hoyer-Hansen et al., 1997) and, depending on the 
exact cleavage sites, exposure of a chemotactically active fragment (Fazioli et al., 1997; 
Gargiulo et al., 2005). Taken together, uPAR seems to accommodate its corresponding 
ligand through a great conformational plasticity.  
The functional epitope for uPA has been identified for the human uPAR by 
systematic alanine scanning mutagenesis (Gardsvoll et al., 2006). In details, nine 
residues in uPAR D1 (Arg25, Thr27, Leu40, Lys50, Thr51, Arg53, Leu55, Tyr57 and 
Leu66), eleven residues of D2 (Asp102, Ser104, Glu106, Val125, Thr127, Asp140, 
His143, Leu150, Pro151 and Leu168) and three residues of D3 (Met219, Gly227 and 
Phe256) displayed a ≥ 2.5 fold increase in the dissociation rate constant upon alanine 
substitution. This analysis clearly emphasized the important role of uPAR D2 in uPA 
binding. 
The similarity of the ternary complex suPAR-ATF-SMB with the suPAR-ATF 
structure confirmed the notion that SMB binding doesn’t perturb the structure of 
suPAR-uPA interface (Huai et al., 2008). The structure showed in fact that uPA 
occupies the central cavity of the receptor, whereas SMB binds the outer site. On the 
other hand the receptor occupancy by uPA does affect the binding of SMB to uPAR, as 
the suPAR-vitronectin affinity in the absence of uPA is reduced (Gardsvoll and Ploug, 
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2007; Sidenius et al., 2002). uPAR oligomerization was proposed to explain this uPA 
effect on VN binding to uPAR (Sidenius et al., 2002). However it is possible that uPA 
has a role in stabilizing the active conformation of uPAR, and this may explain the 
effect of uPA on SMB binding. The VN-binding surface of uPAR was previously 
mapped using a single-site alanine-scanning point mutation library of either purified 
suPAR (Gardsvoll and Ploug, 2007) or full-length uPAR expressed on HEK 293 cells 
(Madsen et al., 2007). In both studies, uPAR residues Try32, Arg58, Ile63 of D1 and 
Arg91, Tyr92 of the D1-D2 linker region were identified as key residues for SBM 
binding in the presence of uPA (Fig. 3). These results were consistent with the suPAR-
ATF-SMB structural model. 
 
 
 
 
Figure 3: Location of the VN-binding site on the crystal structure of uPAR.  
 
A surface representation of the uPAR structure is shown in gray, and the positions of the alanine-
substituted residues that cause a strong reduction in VN binding using purified proteins are indicated in 
red. For comparison, a series of residues located in the uPAR ligand binding cavity and known to be 
involved in uPA binding are indicated in yellow. The most C-terminal residue (Q279) that is likely to be 
located close to the GPI anchor of membrane-tethered uPAR is indicated in cyan. The left panel is a 
“front” view of the uPA-binding cavity and the right panel is a “top” view (front view rotated 90° toward 
the observer). The images were constructed using the coordinates deposited in the Protein Data Bank 
(PDB) with the code number 1YWH and the MacPyMOL software (http://pymol.sourceforge.net). Figure 
taken from (Madsen et al., 2007). 
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Species selectivity of the uPA-uPAR interaction 
Whereas SMB binding is not compromised by species differences (Lin et al., 2010), 
biochemical analysis of the binding properties for human and murine components 
revealed that the uPA-uPAR interaction exhibits species specificity. This species barrier 
has to be taken into account when testing the functional role of uPAR in proteolysis and 
signaling in vivo, i.e. during cancer invasion and metastasis using xenotransplanted 
tumor models. A detailed analysis of the ligand-binding interface in the crystal structure 
solved of human and murine uPA-uPAR complexes helped to identify the uPA residues 
responsible for the species selectivity (Lin et al., 2010). The mATF-muPAR crystal 
structure revealed that the interaction between uPAR and uPA is governed by the burial 
of the β-hairpin from the growth factor-like domain (GFD) module of ATF. Within this 
region just four positions differ between man and mouse, i.e. Asn27/Arg28 and 
His29/Arg30 (site 1) Asn22/Tyr23 and the Trp30/Arg31 (site 2). The humanization of 
just two of these positions, i.e. Tyr23→Asn and Arg31→Trp was able to swap the 
kinetic rate constants for the interactions between muPA and human or murine uPAR, 
thus demonstrating a clear structure-activity relationship for site 2 (Lin et al., 2010). 
Concordantly, it was also possible to graft the reciprocal species selectivity by 
introducing the equivalent mutations in huPA (Asn22→ Tyr, Trp30→Arg) (Lin et al., 
2010).  
As reported in the previously described crystal structure, uPA-binding occupies 
a large cavity that requires all three uPAR domains for its assembly. Despite this, just a 
mutation of the residue Glu31 in muPAR to Leu, the corresponding amino acid in 
huPAR, was sufficient to increase the receptor affinity for huPA. Glu31, in fact, forms a 
hydrogen bond to the essential Arg31 at site 2 of the bond mGFD, giving stability to the 
muPA-muPAR complex. This Glu31→Leu mutation in muPAR also rescued 
completely the loss of high affinity binding muPA Arg31→Try (Lin et al., 2010). 
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Vitronectin (VN) 
 
Vitronectin expression 
VN was discovered as the “serum spreading factor” (Holmes, 1967). The main site of 
VN biosynthesis is the liver; however, VN can also be produced by platelets (Preissner 
et al., 1989) and monocytes/macrophages (Hetland et al., 1989). VN is circulating in the 
blood stream at high concentration of 200-500 µg/ml (Preissner et al., 1985). VN in the 
blood exists as a monomer, but is converted into a multimeric form when incorporated 
into the ECM. VN is found in loose connective tissue of many organs, blood vessel 
walls, lymph nodes, and in the stroma of lymphatic tissue (Hayman et al., 1983), (Reilly 
and Nash, 1988). Increased VN deposition is found in reactive and fibrotic tissue 
(Reilly and Nash, 1988), atherosclerotic plaques (Niculescu et al., 1989) and in several 
tumors (Loridon-Rosa et al., 1988), (Gladson and Cheresh, 1991), (Gladson et al., 
1995), (Maenpaa et al., 1997). Accordingly, VN has been implicated in a variety of 
physiological and pathological processes, including haemostasis (Thiagarajan and 
Kelly, 1988), angiogenesis (Brooks et al., 1994a), (Brooks et al., 1994b; Brooks et al., 
1995), rheumatoid arthritis (Tomasini-Johansson et al., 1998) and tumor cell invasion 
(Desgrosellier and Cheresh; Nip et al., 1992). 
 
Vitronectin gene 
The human VN gene is composed of 4.5-5 kb pairs and contains eight exons and seven 
introns, from which a 1.7 kb pair transcript is derived. It encodes a molecule of 459 
amino acids, which are preceded by a 19 amino acid signal peptide. The molecular 
weight of human VN is 75 kDa and contains three glycosylation sites (Schvartz et al., 
1999). VN is post-translationally modified by sulfatation (Jenne et al., 1989), 
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phosphorylation (Schvartz et al., 2002; Seger et al., 1998; Seger et al., 2001), and N-
linked glycosylation (Sano et al., 2007).  
Despite the expression during embryogenesis, it should be noted that deletion of 
the VN gene in mice is compatible with normal development and fertility (Zheng et al., 
1995). 
 
Structure of vitronectin 
The VN molecule is composed of several domains and binding epitopes (Fig 4). The N-
terminal part of VN contains a SMB domain (residue 1-44), holding the high affinity-
binding site for both uPAR and PAI-1 (residues D22, L24, Y27, Y28) (Fig. 4) 
(Schroeck et al., 2002; Seiffert and Loskutoff, 1991), followed by a region containing 
an Arg-Gly-Asp (RGD) motif (residues 45-47), which mediates the attachment and 
spreading of cells to the ECM through the binding to specific integrins (αvβ1, αvβ3, 
αvβ5, αIIbβ3) (Humphries et al., 2006; Preissner, 1991). Adjacent to the RGD motif 
occurs a highly acidic region (residues 53-64), containing the binding site for the 
antithrombin III complex (TAT) and the collagen-binding domain (Izumi et al., 1988). 
An ionic interaction between this acidic region and the basic region (residues 348-379) 
at the carboxyl-terminal domain is probably involved in stabilizing the three-
dimensional structure of VN, and in the formation of its multimers. The major part of 
vitronectin contains seven hemopexin-type repeats (Jenne and Stanley, 1987) that 
accommodates in the carboxyl-terminal edge the binding site to heparin (Liang et al., 
1997), glycosaminoglycans (Cardin and Weintraub, 1989) and plasminogen (Kost et al., 
1992).  
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Figure 4: Vitronectin structure. 
 
Localization of the binding domains of vitronectin towards various ligands; the binding sites for 
plasminogen activator inhibitor-1 (PAI-1), urokinase receptor (uPAR), integrins, thrombin±antithrombin 
III complex (TAT) and collagen are located in the N-terminus of the molecule, while the binding domains 
for plasminogen, heparin and PAI-1 are located in the carboxyl terminal edge. Figure adapted from 
(Schvartz et al., 1999). 
 
 
 
The crystal structure of PAI-1 in complex with the SMB domain of VN has been 
solved and suggests that PAI-1 binding to VN may sterically interfere with integrin 
binding (Zhou et al., 2003). Indeed, in systems using purified proteins the interaction 
between integrins and VN can be fully blocked by PAI-1; however endothelial -and 
smooth muscle cell adhesion to VN is only partially inhibited by PAI-1; suggesting 
contemporaneous binding of PAI-1 and integrins to VN (Stefansson et al., 2007). Then 
again, formation of the ternary VN-PAI-1-αvβ3-complex in endothelial -and smooth 
muscle cells did not occur after treatment with cytochalasin D, a drug disrupting the 
actin cytoskeleton. This suggests a model in which integrins within focal adhesions 
(FA) sites are rigidly held by the cytoskeleton thus generating sufficient force to access 
the RGD-motif in VN by physically displacing PAI-1 without entirely removing it from 
the adjacent SMB domain (Stefansson et al., 2007).  
VN exists as monomers and multimers (Stockmann et al., 1993), of which the 
latter is considered to be the active form, as defined by its ability to bind heparin, PAI-1 
and uPAR. Multimeric VN exists predominantly incorporated into the ECM and is 
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recognized by cell surface receptors, like integrins and uPAR, where it supports cell 
adhesion, migration and invasion. On the contrary, these binding sites are inaccessible 
on monomeric VN, which accounts for the majority of VN in the plasma (Preissner and 
Seiffert, 1998). It is estimated that only 2% of plasma VN exist in an activated form, 
although it is not clear whether these 2% is able to bind ligands (Izumi et al., 1989). 
Interesting however, is the fact that VN inside the α-granules of platelets, when released 
by exocytosis, is presented in an active form (Seiffert and Schleef, 1996). Consequently, 
the biological functions of VN, and its binding properties to different ligands and cells, 
are tightly dependent on its conformational state(s). The exact structural alterations 
responsible for its many functions are still poorly understood; however, it is believed 
that partially cryptic binding sites in monomeric VN become exposed upon 
multimerization i.e. the SMB domain and the RGD motif. The transition from the 
monomeric to the multimeric form is often induced by interactions with heparin, PAI-1 
(Seiffert and Loskutoff, 1996), and the thrombin-antithrombin complexes, and is 
believed to involve conformational changes in both the N-terminal acidic part and the 
C-terminal basic part of the molecule (Preissner and Seiffert, 1998). Likewise, 
phosphorylation (Seger et al., 2001), glycosylation (Sano et al., 2007) and proteolytic 
degradation of vitronectin (Chain et al., 1991) have been shown to modulate its 
conformation and function. The assembled multimers are deposited at sites of increased 
vascular permeability or injury (Seiffert, 1997) where they interact with various binding 
partners i.e. collagen, glycosaminoglycans, PAI-1, uPAR and integrins. 
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uPAR and the plasminogen activation system 
 
 Proteolytic degradation of the extracellular matrix plays a crucial role in cancer 
progression. The malignant progress of tumor invasion and metastasis requires the 
extensive making and breaking of the cell-cell and cell-ECM contacts as well as the 
degradation of ECM components that poses the physical barrier in the direction of 
invasion and migration. This degradative interplay often mimics the one observed in the 
tissue of origin during non-neoplastic remodeling processes, insinuating that cancer 
invasion may be regarded as uncontrolled tissue remodeling (Dano et al., 1999). 
Proteolytic remodeling of the ECM involves a complex interplay between 
cancer cells and stromal cells and it is accomplished by a number of proteases with 
different activities and substrate specificities. Best known are the plasminogen (Plg) 
activation system that leads to the formation of the serine protease plasmin. In 
mammals, two different plasminogen activators have been identified, urokinase-type 
and the tissue-type plasminogen activators (uPA and tPA). Even though both 
plasminogen activators catalyzed the same reaction, uPA is thought to be more 
important in tissue remodeling and tPA in vascular fibronolysis.  
uPA is released from the cells as an inactive proenzime, pro-uPA. Pro-uPA is a 
single glycoprotein chain of 52 kDa, composed of three crucial regions: the growth 
factor-like domain (GFD, residues 10 to 43) and the kringle domain (residues 50 to 132) 
that together form the N-terminal domain (ATF), which binds uPAR, and the C-
terminal domain (CTF), which is endowed with catalytic activity. uPAR binds both pro-
uPA and uPA with high affinity (0.1-1 nM) (Ellis et al., 1989). Once activated, uPA is 
able to convert the plasminogen to active plasmin, which than breaks down ECM 
components directly or indirectly through activation of pro-matrix metalloproteases 
(pro-MMPs) (Fig. 5). 
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Figure 5: Schematic representation of the role of uPAR as a proteinase receptor. 
 
At the leading edge of migrating cells uPAR binds pro-uPA, which is than converted to active uPA. 
Active uPA proteolytically converts the inactive zymogen plasminogen to active plasmin, which breaks 
down ECM components or activates latent growth factors such as transforming growth factor β1 (TGF-
β1). Plasmin can also degrade the ECM indirectly through the activation of pro-MMPs. Figure taken from 
(Blasi and Carmeliet, 2002). 
 
 
 
It is interesting that several components of the fibrinolytic pathway modulate 
uPAR activity. For instance, uPA, plasmin or MMPs, are all able to cleave membrane 
bound and soluble uPAR (Andolfo et al., 2002; Hoyer-Hansen et al., 1997) (Fig. 6). The 
result of the proteolytic cleavage of uPAR is the release of the D1 fragment from the 
rest of the receptor. This phenomenon impairs plasminogen activation as the co-
localization between plasminogen and pro-uPA is lost and produces the uPAR fragment 
D2D3 fragment, which exploits a potent chemotactic activity (Fazioli et al., 1997) 
(Fig.6). 
The plasminogen activator inhibitor-1 (PAI-1) also binds and regulates uPAR 
functions (Cubellis et al., 1989; Ellis et al., 1990). Indeed PAI-1 binds active uPA and 
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forms a uPA:PAI-1 covalent complex. This complex interacts with uPAR and another 
transmembrane receptor, a member of the low-density lipoprotein (LDL)-receptor-
related protein (LRP)-protein family, which than drives the internalization of the uPAR-
uPA:PAI-1 complex. In this process the uPA:PAI-1 complex is degraded (Cubellis et 
al., 1990), (Olson et al., 1992) and uPAR is recycled to the cell surface (Nykjaer et al., 
1997).  
The ECM not only determines tissue architecture but also serves as a reservoir 
for growth factors (Aumailley and Gayraud, 1998), contributing to organ formation, 
growth, apoptosis and most likely cancer dissemination (Liotta and Kohn, 2001). Thus 
the proteolytic degradation of the ECM contributes to the release of matrix-bound 
growth factors and signaling molecules (Ramirez and Rifkin, 2003). Of particular 
interest is the activation of bFGF (Saksela and Rifkin, 1990), FGF-2 (Ribatti et al., 
1999), TGF-β1 (Lyons et al., 1990) (Fig. 5), HGF (Naldini et al., 1992) and IGFBP-4 
(Remacle-Bonnet et al., 1997), which all can be activated by the PA system.  
Besides concentrating pro-uPA to the cell surface, uPAR is capable of localizing 
the protein to specific sites where plasminogen activation is required, since uPAR is 
usually localized at the leading edge of migrating cells (Estreicher et al., 1990; Romer et 
al., 1994). 
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Figure 6: uPAR cleavage and shedding. 
 
The urokinase receptor (uPAR) consists of three internally disulphide bounded domains and is attached to 
the cell surface by a GPI-anchor. Soluble uPAR (suPAR) is released from the plasma membrane by 
cleavage of the GPI anchor (uPAR shedding). Both uPAR and suPAR can be cleaved in the region that 
links domains D1 and D2 (scissors) to yield a D1 and D2D3 fragment (uPAR cleavage). Figure taken 
from (Blasi and Carmeliet, 2002). 
 
 
 
Another player in the plasminogen activation system is the ECM protein 
vitronectin (VN). PAI-1 binds with high affinity to VN in a reaction that stabilized PAI-
1 in its active conformation (Knudsen and Nachman, 1988). VN bound PAI-1 can still 
bind and inactivate uPA, but the formed uPA:PAI-1 complex has only low affinity for 
VN and is rapidly released (Deng et al., 1996). The binding sites for PAI-1 on VN 
overlaps with the one for uPAR, also capable of binding VN, and the binding of these 
two proteins is competitive and mutually exclusive (Deng et al., 1996), (Seiffert and 
Loskutoff, 1991). Numerous studies indicate that the uPA-system is involved in cancer. 
uPAR and uPA are over-expressed in human tumors (Dano et al., 2005). During tissue 
remodeling and cancer invasion functional redundancy is observed between 
extracellular proteases and often a synergistic effect is observed (Dano et al., 2005).  
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Besides this, proteolysis-independent cancer invasion have been observed by the 
ability of cancer cells to switch from a mesenchymal to an amoeboid type of migration 
surpassing the need of ECM degradation (Sahai and Marshall, 2003), (Wolf et al., 
2003). 
 
 
uPAR and signaling 
 
In addition to regulating proteolysis, many studies show that uPAR is also a signaling 
receptor that promotes cell motility, invasion, proliferation and survival (Fig. 7). 
Although signaling through uPAR can involve uPA-uPAR binding, it is typically 
independent of uPA proteolytic activity. Another PA system player that takes part in the 
uPAR signaling is VN. Studies using alanine scanning mutagenesis have shown that 
only the residues of the VN-binding site are essential for uPAR to stimulate the actin 
cytoskeletal rearrangements required for cell spreading and migration (Madsen et al., 
2007). However, lacking transmembrane and intracellular domains, uPAR must 
cooperate with transmembrane receptors to activate intracellular signaling. Considerable 
evidence suggested integrins to be uPAR-signaling co-receptors. Integrins are a large 
family of heterodimeric adhesion receptors that mediate cell attachment to several ECM 
components, including VN. uPAR co-immunoprecipitates with integrins and integrin-
associated signaling molecules such as FAK and Src family kinases (Wei et al., 1996). 
Moreover, binding of different integrins to uPAR confers specificity to the signaling 
output of uPAR, activating one pathway instead of another. Even if all these approaches 
associate integrin pathways to uPAR, they do not prove a physical interaction between 
uPAR and integrins. uPAR binding to VN is independent of integrin engagement with 
VN, as mutation of the RGD motif into RAD still supports cell adhesion (Madsen et al., 
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2007). Additionally, treatment with integrin-blocking antibodies, EDTA, and RGD-
blocking peptides fail to inhibit uPAR-mediated cell adhesion to VN (Wei et al., 1994). 
The uPAR affinity for VN is often increased by concurrent binding of uPA or ATF 
(Sidenius et al., 2002). Accordingly, cells expressing low levels of uPAR adhere poorly 
to VN unless saturated with exogenous uPA, while cell expressing high levels of 
endogenous uPAR adhere independently of receptor occupancy (Sidenius and Blasi, 
2000). 
 
 
 
Figure 7: Role of uPAR as signaling receptor. 
 
The urokinase receptor (uPAR) binds uPA and VN. uPAR lacks a cytosolic domain but transmits 
intracellular signals through its association with transmembrane integrins. Figure adapted from (Blasi and 
Carmeliet, 2002). 
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The first uPAR-integrin colocalization to be described involved MAC1, 
expressed in leukocytes, where it regulates migration, differentiation and phagocytosis. 
uPAR expression stimulates MAC1-driven neutrophil and monocyte chemotaxis in 
vitro (Gyetko et al., 1994). In addition, uPAR-deficient mice displayed impaired 
neutrophil infiltration of the lungs in models of pulmonary infection (Gyetko et al., 
2000). uPAR-MAC1 signaling can contribute to the adhesion of macrophages and 
neutrophils to endothelial cells, a prerequisite for extravasation (Gyetko et al., 2000; 
May et al., 1998). 
These findings are particularly interesting within the tumor scenario, which is 
often rich in leukocytes such as macrophages and neutrophils, as such tumor-associated 
leukocytes are important drivers of tumor behavior, including metastasis (Mantovani 
and Pierotti, 2008). 
uPAR has also been found to co-localized with β1 and β3 integrins (Smith and 
Marshall, 2009). Several studies emphasized the distinct roles of uPAR-β1 integrin and 
uPAR-β3 integrin signaling. uPAR- β1 integrin is linked to ERK-dependent tumor cell 
proliferation. Chicken chorioallantoic membrane assay showed that signaling through 
α5β1 integrin is enhanced by uPA-uPAR interaction, leading tumor cell proliferation. 
Interestingly, in the same system, cells lacking uPAR entered a dormant state (Aguirre 
Ghiso et al., 1999; Aguirre-Ghiso et al., 2001), which suggests an important role for 
uPAR in determining whether tumor cells proliferate or become dormant. The uPAR-β3 
integrin complex is proposed to initiate a pathway that involves Src activation and 
p130Cas phosphorylation, thus stimulating actin polymerization and cell protrusion that 
lead to cell motility. VN is often co-expressed with uPAR and β3 integrin in tumors 
(Loridon-Rosa et al., 1988); moreover, in tumor cells and podocytes, uPAR-β3 integrin 
signaling is VN-dependent. This is consistent with the fact that both uPAR and β3 
integrins can bind VN. 
 31 
Role of uPAR and uPA in in vivo fibrinolysis 
 
The fibrinolytic system, also called plasminogen/plasmin system, has been claimed to 
play a role in a variety of phenomena associated with proteolysis, including blood clot 
dissolution (thrombolysis), ovulation, embryo implantation, embryogenesis, and cell 
invasion (Collen and Lijnen, 1991; Vassalli et al., 1991). 
The availability of gene targeted mice deficient in the urokinase type 
plasminogen activator (uPA), urokinase receptor (uPAR), tissue-type plasminogen 
activator (tPA), and plasminogen (Plg) permitted a critical, genetic-based analysis of the 
physiological and pathological roles of the two mammalian plasminogen activators uPA 
and tPA. 
Plg deficient mice are predisposed to severe thrombosis and secondary tissue 
damage but complete embryonic development, survive to adulthood, and are capable of 
reproduction. 
Like Plg-/- mice, mice with combined deficiency in uPA and tPA suffer 
extensive spontaneous fibrin deposition but develop to term, grow to adulthood and 
reproduce (Carmeliet et al., 1994). 
Remarkably, despite the fact that tPA appears to be of primary importance in 
vascular fibrinolysis via its fibrin binding property, mice lacking only tPA experience 
essentially no thrombotic problems (Carmeliet et al., 1994). Similarly mice lacking only 
uPA are generally healthy, but these mice occasionally develop hepatic fibrin deposition 
and ischemic rectal lesions (Carmeliet et al., 1994). Together these findings support that 
fibrinolysis may be the only physiological process for which Plg is essential and both 
uPA and tPA are complementary proteases that are individually capable of effectively 
clearing spontaneous vascular and extravascular fibrin. 
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The uPA receptor concentrates uPA-mediated proteolysis on the cell surface and 
it is well established that the rates of both pro-uPA and Plg activation in vitro are 
dramatically accelerated by the binding of uPA to uPAR (Ellis and Dano, 1991). 
Despite these evidences, uPAR deficient mice do not develop the spontaneous hepatic 
fibrin deposit, ischemic rectal ulcerations, or rectal prolapses observed in uPA-/- mice 
(Carmeliet et al., 1994). Moreover mice with combined uPAR and tPA deficiency do 
not exhibit the wide-range spread fibrin deposition, extensive multi-organ tissue damage 
and severe impairment of wound healing observed in mice with combined uPA and tPA 
deficiency and Plg-/- mice (Bugge et al., 1996). These findings demonstrate that 
receptor-bound uPA plays a role in fibrinolysis but it is effective in general fibrin 
clearance and can support wound healing in a uPAR- and tPA- independent manner. 
Elucidation of the specific functions of uPA-uPAR interaction in vivo has been 
difficult because uPA has important physiological functions that are independent of 
binding to uPAR and because uPAR engages multiple ligands. In a recent study 
Connolly et al. (Connolly et al., 2010) generated a new mouse strain Plau GDFhu/GDFhu in 
which the uPA-uPAR interaction is selectively abrogated, while other functions of the 
protease and its cellular receptor are retained. Analysis of Plau GDFhu/GDFhu mice revealed 
an unanticipated role of the uPA-uPAR interaction in suppressing inflammation 
secondary to fibrin deposition. In contrast, leukocyte recruitment and tissue 
regeneration were unaffected by the loss of uPA binding to uPAR (Connolly et al., 
2010). The obtained results clearly demonstrated that fibrin surveillance by uPA is a 
uPAR-dependent process that cannot be fully compensated by either uPAR-independent 
Plg activation (Bugge et al., 1996) or by activation of Plg by tPA (Carmeliet et al., 
1994). Moreover the novel mouse-strain developed will be a most valuable tool for 
further functional dissection of the uPAR molecule. 
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uPAR and cancer 
 
There is abundant experimental and clinical evidence in the literature supporting a role 
for the PA system in cancer progression. Neoplastic tumors in mice deficient in either 
plasminogen or uPA exhibit slower growth and show less tumor progression than 
similar lesions in wild-type mice (Gutierrez et al., 2000). Transfection of uPAR in 
HEK293 cells enhances metastasis into the lungs of immunodeficient mice in an uPA 
independent fashion (Jo et al., 2009) (Fig. 8). Furthermore, antibodies and inhibitors 
against components of the PA system prevent or reduced metastasis (Ossowski and 
Reich, 1983; Ploug et al., 2001).  
 
 
 
 
Figure 8: uPAR promotes HEK-293 cell metastasis in mice. 
 
A: The number of discernable metastasis to the lungs is plotted for mice injected with empty vector (EV), 
human uPAR-expressing cells (HU1, HU2) or mouse uPAR-expressing cells (MU1, MU2). Lung 
metastasis were determined by counting green fluorescent foci that are at least 100 µm in maximum 
diameter on the surfaces of each lobe (mean ± s.e.m., P<0.01, P value determined by one-way analysis of 
variance test). B: Results obtained with HU1 and HU2 cells or MU1 and MU2 cells were pooled. Figure 
taken from (Jo et al., 2009). 
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The reason that the PA system is an attractive target for cancer therapy is that 
this system is quantitatively more expressed in tumor tissue. High uPAR, uPA and PAI-
I levels have been shown to be adverse prognostic markers in several types of tumors.  
In early studies it was taken for granted that the proteases in tumor tissue were produced 
by the cancer cells. However, further findings suggested that the expression of 
components of the PA system in tumors can occur in tumor cells and/or tumor 
associated stromal cells. Precisely, which cell type synthesizes each of these molecules 
is different in different types of human cancer. In ductal breast cancer and in colon 
cancer uPA is expressed by fibroblast (Nielsen et al., 2001), in prostate cancer by 
macrophages (Pyke et al., 1991; Usher et al., 2005). In contrast, uPA is expressed by 
cancer cells in skin squamous cell carcinomas (Romer et al., 1991). The expression 
pattern of uPAR also differs between different cancers. uPAR is expressed by both 
cancer cells and macrophages in colon cancer (Pyke et al., 1991), primarily by 
macrophages in ductal breast cancer (Pyke et al., 1993), by cancer cells in skin 
squamous cell carcinoma and by macrophages in prostate cancer (Usher et al., 2005). 
Interestingly, the correlation between poor prognosis and expression of protein of the 
PA system is independent of the cell types in which the molecules are produced. These 
evidences suggest that cancer invasion is the result of an interaction between cancer 
cells and stromal cells. The cancer cells that invade are the initiators and probably the 
organizers, but each cell type contributes in a distinct way to the overall process. 
Only few experimental studies on the functional role of stromal cells expression 
and components of the proteolytic system in cancer have been reported, probably 
because this phenomenon is generally poorly mimicked by transplanted tumors and 
there are few good animal models of spontaneous cancer available for study. However, 
studies conducted in genetically induced breast cancer in transgenic mice, that resemble 
the human ductal breast cancer, including the uPA expression by tumor-associated 
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stromal cells, reported as the absence of uPA leads to pronounced decrease in lung and 
lymph node metastasis, indicating an important role of stromally derived of uPA in this 
process (Almholt et al., 2005).  
Since uPAR was discovered to be able to promote cell signaling through the 
interaction with members of the ECM and transmembrane proteins, therapeutic 
targeting of uPAR in cancer could not only interrupt the proteolytic cascade but also 
block the intracellular signaling responsible for the tumor-promoting functions of the 
stroma.  
 
 
Targeting the PA system in cancer 
 
uPAR discovery as a signaling molecule is relatively recent; for this reason most 
of therapies against cancer have been developed to target the proteolytic systems. 
Established therapeutic strategies to inhibit the uPA system are different and include 
inhibitor of the interaction between uPAR and uPA, inhibitor of the uPAR/VN/integrin 
interface and attenuation of uPA activity. Furthermore, transcriptional and post-
transcriptional silencing of uPA system components are novel strategies for inhibition 
of tumor growth. 
Some studies have investigated the antineoplastic effectiveness of anti-uPAR 
antibodies. A syngenic tumor model was produced by inoculation of rat breast 
carcinoma cells Mat B-III overexpressing uPAR into a syngenic rat, which then 
received a polyclonal antibody against the ligand-binding N-terminal domain of rat 
uPAR (Rabbani and Gladu, 2002). Treated rats showed a strong decrease of tumor 
progression. Similar results were obtained from an orthopic mouse model of human 
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pancreatic carcinoma, whose treatment with anti-uPAR monoclonal antibody decreased 
tumor growth and metastasis (Bauer et al., 2005). 
The ATF portion of uPA lacks enzymatic activity and competes with naturally 
occurring uPA for uPAR binding. Transfection of human ATF cDNA in human lung 
carcinoma cells was shown to significantly reduce their invasive capacity in vitro and to 
prevent lung progression in a spontaneous metastasis model (Zhu et al., 2001). Similar 
results were demonstrated by another study using a defective adenovirus conveying a 
secretable version of the ATF of uPA (AdmATF) (Li et al., 1998). In this study, 
intratumoral injection of AdmATF into pre-established human breast cancer grafted in 
athymic mice exhibited an important reduction of tumor neovascularization, together 
with an inhibition of tumor growth. 
Besides ATF, synthetic linear and cyclic peptides reproducing the receptor-
binding region of ATF have been designed. An early study demonstrated the ability of 
murine uPA-derived peptides (residues 17-34) to inhibit metastatic colonization of 
murine Lewis Lung carcinoma cells inoculated subcutaneously into syngenic mice 
(Kobayashi et al., 1994). In another study, treatment of nude mice with cyclo19,31-uPA19-
31, a cyclic form of the minimal essential peptide uPA19-31, reduced the growth of human 
MDA-MB231 breast cancer cells when compared with the vehicle-treated control group 
(Sperl et al., 2001). 
The use of recombinant soluble truncated forms of uPAR (suPAR) was another strategy 
to prevent tumor-associated proteolysis. In xenogenic mouse models, a reduction of 
primary tumor growth, tumor spread and metastasis occurred for ovarian cancer as well 
as breast cancer (Kruger et al., 2000). 
Results to disclose the possibility of inhibiting tumor growth by suppression of 
uPA activity were achieved with anti-uPA antibodies and synthetic small molecules 
inhibiting the uPA system. Inhibition of receptor-bound uPA by specific anti-uPA 
 37 
antibodies caused a significant suppression of proliferation in human melanoma cell line 
GUBSB (Kirchheimer et al., 1989). The WX-UK1, is one of the most potent uPA 
inhibitors described so far. First studies demonstrated that WX-UK1significantly 
reduced the number of metastatic lesions and tumor progression in a resected, 
spontaneously metastasizing rat mammary tumor model (Kirchheimer et al., 1989). 
WX-UK1 is currently under evaluation in phase II. 
Many cytokines and growth factors induce the expression of components of the 
uPA system. Inhibition of cytokines and growth factors binding to their receptors or 
inhibition of their intracellular signaling may prevent uPA/uPAR-dependent processes. 
An example is given by studies of compounds blocking the EGFR activity. The EGFR 
family is overexpressed in a lot of human cancers and it is known to be involved in the 
transduction of uPAR stimuli. Results obtained with prostate cancer lines documented 
that tyrosine kinase inhibitors competitively bind the ATP pocket of EGFR, inducing a 
drastic reduction of uPA and uPAR mRNA and protein levels. This effect was 
associated with the inhibition of invasion potential of tumor cells and metastasis 
formation in nude mice studies (Festuccia et al., 2005). 
 In other faces of oncology, the uPA/uPAR system has been targeted with gene 
therapies such antisense nucleotide inhibition and siRNA. 
Down-regulation of uPAR levels by antisense strategy using an adenovirus construct 
(Ad-uPAR) inhibited tumor cell invasion and metastasis in non-small cell lung cancer 
cell lines (Lakka et al., 2001). In vivo antisense uPAR mRNA also impaired colon 
cancer metastasis (Wang et al., 2001). Intraperitoneal and intratumoral administration of 
interfering RNA plasmid targeting uPAR demonstrated remarkable regression of pre-
established breast tumors in mice (Fig. 9) (Kunigal et al., 2007).  
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Figure 9: Therapeutic Effect of siRNA for uPAR and MMP-9.  
 
MDA-MB231 cells (5-6×106 cells in 100 µL of phosphate-buffered saline or serum-free medium) were 
injected into the breast pad of nude mice and kept under observation for tumor growth. Tumors were 
allowed to grow until they reached 5 to 6 mm. At this point, tumors were randomized into several 
groups receiving treatment with SV, puPAR, pMMP-9, or pUM (plasmid siRNA vector for uPAR and 
MMP-9) (150 µg of each vector was injected intratumorally). A: Animals injected with various 
constructs. B: Tumors from these animals were dissected 4 weeks after injection with these constructs. C: 
Semiquantification of tumor volume in control, SV, puPAR, pMMP-9, and pUM-treated groups at 4 to 6 
weeks after treatment. Data shown are mean ± S.D. values from 5 to 6 animals from each group. Figure 
taken from (Kunigal et al., 2007). 
 
 
Virus- and toxin-associated anticancer therapies are new and promising 
approaches for the treatment of cancer. 
An example of oncolytic virus engineered to specifically target tumor cells is 
given by Jing and co-workers. The authors characterized a novel Edmonston vaccine 
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strain oncolytic MV (MV-Edm) fully retargeted against uPAR. More precisely, they 
display the uPAR-binding ATF of either human (MV-h-uPA) or murine (MV-m-uPA) 
uPA into the COOH- terminus of mutant MV-H glycoprotein, which lacks the ability to 
attach to its endogenous receptors. They showed that MV-h-uPA significantly delayed 
tumor progression and improved survival in a breast cancer xenograft model. Moreover, 
MV-m-uPA was able to target tumor capillaries in vivo (Jing et al., 2009). 
Among the new therapeutic strategies that have been exploited to achieve tumor-
restriction action, one of the most common is the conjugation of antibodies, cytokines 
and growth factors with bacterial or plant toxins. Liu and colleagues (Liu et al., 2001) 
constructed mutated anthrax toxin-protective antigen (PrAg) proteins in which the furin 
cleavage site is replaced by sequences cleaved specifically by uPA. These uPA-targeted 
PrAg proteins were activated selectively on the surface of uPAR-expressing tumor cells 
in the presence pro-uPA and plasminogen. The activated PrAg proteins caused 
internalization of a recombinant cytotoxin, thereby killing the uPAR-expressing tumor 
cells.  Data obtained from in vivo studies of uPA-activated PrAg proteins were 
extremely encouraging. In fact, engineered PrAg had a strong anti-tumor activity when 
injected adjacent to tumor nodules. These evidences strongly support the mutated PrAg 
proteins as a new therapeutic agent for cancer treatment (Liu et al., 2005). 
 
 
PA system in innate and adaptive immunity 
 
Levels of various components of the PA system are upregulated during severe 
infections. This evidence supports a role for this system in both innate and adaptive 
immune-mediated responses.  
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Indeed, bacterial products, such as endotoxin, as well as pro inflammatory 
cytokines, including IL-1β and TNF-α, whose release is increased in case of severe 
infection, elicit uPA expression and secretion by several cells, such as epithelial and 
endothelial cells monocytes and neutrophils (Blasi, 1993). 
uPAR also participates in the initiation of the innate immune response by 
regulating cell adhesion and migration. In uPAR deficient mice, macrophages and 
neutrophils failed to infiltrate the lungs of mice infected with Streptococcus pneumonia 
(Rijneveld et al., 2002) or Pseudomonas aeruginosa (Gyetko et al., 2000) (Fig. 10). 
 
 
 
 
Figure 10: Comparison of neutrophil recruitment in WT and uPAR-/- mice in response to P. 
aeruginosa pneumonia.  
 
WT and uPAR-/- mice were IT inoculated with PBS or P. aeruginosa, and the numbers of neutrophils 
present in BAL fluid were determined 4 and 8 h later. Neutrophils in PBS-inoculated mice were 
quantified at 4 h post-IT inoculation. In black columns WT mice; in stripped columns, uPAR-/-. Data are 
expressed as the mean ±s.e.m., *, p=0.0003 (n=12); **, p =0.0011 (n=5). Figure taken from (Gyetko et al., 
2000). 
 
 
 
The observation that uPAR-dependent cell recruitment was in some cases 
independent of uPA (Gyetko et al., 2001; May et al., 1998), and that uPAR- and uPA-
knockout mice have different susceptibilities to several pathogen infections (Gyetko et 
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al., 2000; Rijneveld et al., 2002), indicates that uPAR and uPA might operate at 
different steps and by different pathways. Furthermore, the finding that PA1-1 or 
plasminogen deficient mice showed optimal inflammatory cell migration and host 
defense during Pneumococcal pneumoniae infection (Rijneveld et al., 2003) indicates 
that uPA and uPAR favor innate immune responses mostly by promoting inflammatory 
cell activation and migration rather than through their fibrinolytic function. 
uPA and uPAR also participate in the initiation of adaptive immune responses. 
T-cells expression of both uPA and uPAR are rapidly upregulated during T-cell 
activation (Bianchi et al., 1996; Nykjaer et al., 1994). Moreover uPAR is expressed by 
antigen presenting cells (APCs), such as dendritic cells (DCs), monocytes and 
macrophages (Blasi, 1999; Plesner et al., 1997). Thus the concomitant expression of 
uPA and uPAR by T-cell and APC supports the possibility that the PA system 
participates in T-cell priming. This possibility is supported by data obtained both in 
vitro and in vivo. In fact, splenocytes derived from uPA-deficient mice elicit only 
suboptimal T-cell activation and proliferation in vitro (Gyetko et al., 1999). Moreover, 
blocking uPAR on the surface of DCs and monocytes lowers the co-stimulatory 
capabilities of these cells (Stonehouse et al., 1999; Woodhead et al., 2000). 
Furthermore, in absence of uPA, T helper effetor lymphocytes fail to differentiate in 
response to pathogen challenge in vivo (Gyetko et al., 2002), (Gyetko et al., 2004). 
uPA-uPAR could also promote T-cell effector function at the site of infection. For 
instance, uPA can activate latent proinflammatory cytokines, such as pro-TGF-β, pro-
IL-1 and pro-IL-6, or MMPs, and thus favor the local inflammatory reaction (Vaday and 
Lider, 2000). Finally, uPA-dependent fibrinolysis and tissue remodeling, by eliciting the 
degradation of several tissues components, might favor antigen presentation, and thus 
T-cell re-activation in situ. By contrast uPAR might favor the recruitment of activated T 
cells in infected tissues. Indeed, blockade of uPAR expression by antisense nucleotides 
 42 
hampers leukocyte migration in vitro (Gyetko et al., 1994). In vivo, T-cell recruitment to 
the lung is defective in uPAR-Knockout mice (Gyetko et al., 2001) (Fig. 11). 
 
 
 
 
 
 
Figure 11: Comparison of recruitment of WT and uPAR-/- lymphoblast to the lungs of WT 
recipient mice.  
 
WT or uPAR-/- CMFDA-labeled lymphoblasts were i.v. infused into SRBC-primed WT mice 3 days 
after they were inoculated with SRBC IT. Eighteen hours later the number and percentage of CMFDA+ 
lymphocytes recruited to the lungs of the WT recipient mice were determined. WT lymphocytes recruited 
to the lungs of the WT recipient mice were determined. WT lymphoblasts are represented by the filled 
bars and uPAR-/- lymphoblast are represented by the hatched bars. Data are represented as mean ±s.e.m., 
*, p=0.05; **, p =0.007 (n=6). Figure taken from (Gyetko et al., 2001). 
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Material and Methods 
 
 
Antibodies 
Polyclonal antibody against muPAR (SI420), muPAR D1 (BR 4.8) and muPAR D1D2 
(AK 17.1) were used in FACS analysis and Western blot (Tjwa et al., 2009). Rat 
monoclonal anti-mouse F4/80 FITC-conjugated (Abcam) was used for Bone Marrow-
derived macrophages IF. Polyclonal antibodies against total and phosphorylated 
ERK1/2, pY410-p130Cas, and secondary antibodies anti–mouse HRP and anti-rabbit 
HRP were from Cell Signaling Technology. Antibody against mouse vinculin was from 
Sigma-Aldrich. Hamster anti-mouse CD31/PECAM was from Millipore. Goat anti-
mouse VE-cadherin (C-19) was from Santa Cruz. Donkey anti-mouse-IgG-Cy3, 
Donkey anti-mouse-IgG-Cy5, Donkey anti-Goat-FITC and Goat anti-Hamster-Cy3 
were from Jackson ImmunoResearch Laboratories. Phalloidin-FITC and biotinylated-
AnnexinV were from Sigma-Aldrich. SA-APC was from eBioscience.  
 
Cloning of mouse uPAR and expression vectors construction 
A full-length mouse uPAR cDNA (muPAR, (Kristensen et al., 1991)) was amplified 
with primers mupKpn/muPARre and cloned KpnI/NotI in pcDNA5/FRT-TO 
(Invitrogen) generating the expression vector pFRT/TO-muPAR. The muPARΔD1 
deletion mutant was generated by co-amplification (primers mupKpn/muPARre) of two 
PCR products generated using primer-pairs mupKpn/mD1rev and mD1/muPARre and 
cloning as described for full-length mouse uPAR. This procedure deletes the D1-coding 
region (residues 1-84) generating a truncated D2D3-receptor having the same N-
terminal (Gly85) as that generated by uPA or limited plasmin cleavage of the D1-D2 
linker region (Andolfo et al., 2002). 
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The VN(1–66)/Fc fusion protein was generated by attaching the first 66 amino 
acids of mature human VN to a constant region of a human IgG. Primers and templates 
were as follows: a vector containing part of the VN cDNA (pTrx-VN(1–97) (Deng et 
al., 1996)) were amplified with oligonucleotides VN(1–66)u and VN(1–66)d and a 
vector containing an Fc region of human IgG (pIG-1 (Fawcett et al., 1992)) were 
amplified with primers FcU and FcD. The VN(1–66) (Kpn1–Xho1) and Fc (Xho1–Not) 
fragments were assembled in Kpn1–Not1 digested pcDNA5/FRT-TO (Madsen et al., 
2007). The correct sequences of the complete coding regions of all constructs were 
verified by sequencing.  
The primers are shown in appendix A. 
 
Site directed mutagenesis 
Alanine substitutions were generated by site-directed mutagenesis according to the 
QuickChange II Site-directed mutagenesis protocol (Stratagene). Multiple rounds of 
mutagenesis were used to generate constructs carrying multiple substitutions. 
Expression vectors encoding soluble uPAR variants were generated by a second round 
of site-directed mutagenesis changing codon 284 of uPAR into a stop-codon (oligo pair 
A284Stop).  Oligos used to generate muPAR mutants are shown in appendix A. 
 For the generation of cell lines with constitutive expression of the different 
uPAR-variants the coding regions were transferred KpnI/NotI to the pcDNA5/FRT 
vector (Invitrogen). 
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Cell Lines 
Chinese Hamster Ovary (CHO) cells 
Parental CHO cells Flp-In were cultured in vitro by subconfluent passage in Ham’s F12 
medium (Invitrogen), supplemented with 10% Fetal Calf Serum (FCS, Hyclone), 
100U/ml penicillin, 100U/ml streptomycin, 5mM Glutamine (EuroClone) and 100 
µg/ml zeocin (Invitrogen) at 37°C in 5% CO2.  
Transfections were performed with a 1:10 ratio of pcDNA5/FRT/TO-based 
expression vector and the Flp recombinase expression vector pOG44 (Invitrogen) using 
FuGENE 6 (Roche). When cotransfected with the pcDNA5/FRT plasmid into a Flp-In 
mammalian host cell line, the Flp recombinase expressed from pOG44 mediates 
integration of the pcDNA5/FRT vector containing the gene of interest into the genome 
via Flp Recombination Target (FRT) sites. 
 Stable CHO Flp-In transfectants were selected in medium lacking zeocin using 
300 µg/ml ml hygromycin B (Roche). 
 
HEK293 Flp-In T-Rex cells 
Parental HEK293 Flp-In T-Rex cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, BioWhittaker), supplemented as for CHO Flp-In cells, but plus 5 
µg/ml Blasticidin (Invitrogen). The procedure of transfection was the same as CHO Flp-
In cells, but stable transfectants were selected in medium lacking zeocin using 150 
µg/ml hygromycin B. Expression in HEK293 Flp-In T-Rex was induced by adding 1 
µg/ml tetracycline (Sigma-Aldrich) to the medium overnight. 
For in vivo experiments, parental HEK293 Flp-In T-Rex cells were transfected 
with cytosolic GFP expression vector (pEGFP-N1, Clonetech) and subjected to single 
cell cloning by adding 1 mg/ml G-418 (Invitrogen) to the medium. These cells were 
further transfected with pcDNA5/FRT/TO-based expression vector, containing full-
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length muPAR, muPARW32A, muPARΔD1 or with empty vector (mock), as previously 
described, and selected in 150 µg/ml hygromycin B. 
 
Rat smooth muscle cells (RSMC) 
RSMC were a kind gift of Dr. Bernard Degryse. RSMC culture medium consisted of 
DMEM supplemented with 10% FCS, 100 U/ml penicillin, 100 U/ml streptomycin, 5 
mM Glutamine. 
 
Lung endothelial cell (EC) derivation and culture 
Lungs of uPAR+/+ and uPAR-/- adult mice were removed aseptically, rinsed in PBS, 
minced and than digested in DMEM containing collagenase A (1.5 mg/ml, Roche) and 
DNaseI (25 mg/ml, Roche). The enzymatic digestion was performed in agitation at 
37°C for 4 h. The resulting cell suspension was further dissociated by gentle pipetting, 
filtered through a sterile 70 µm nylon mesh and centrifuged at 1200 rpm for 5 minutes. 
Cell pellet was then incubated in 0.2% NaCl for 1 minute to lyse red blood cells and 
than overlaid with 1.8% NaCl to restore physiological conditions. After 3 washes in 
PBS, the cells were plated in culture medium on 24-well plates (0.5 to 1 x 106 
cells/well) plate for 1 lung) pre-coated with 0.1% gelatin and incubated in 37°C, 5% 
CO2 incubator. After 48 h cells were immortalized with polyoma middle T (PmT) as 
previously described (Garlanda et al., 1994).  Briefly, cells were incubated with 300 
µl/well of PmT supernatant in the presence of 8µg/ml polybrene (Sigma-Aldrich). The 
virus-containing medium was replaced 3 h later with fresh complete medium. 
Cells were routinely cultured in DMEM supplemented with 20% FCS, 100U/ml 
penicillin, 100U/ml streptomycin, 5mM Glutamine, endothelial cell growth supplement 
(5mg/ml, home-made from calf brain) and heparin (100 mg/ml, Sigma-Aldrich), on 
0.1% gelatin (Difco)-coated tissue culture plates. 
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Isolation and culture of bone marrow-derived macrophages (BMMs) 
BMMs were isolated from mice whose genotypes were uPAR+/+ (Wt) and uPAR-/- 
(Ko). Red blood cells lysis was performed as for EC. Cells were seeded at 1x106 cells 
per 100mm dish (Corning) in 5ml of macrophage growth medium, consisting of DMEM 
medium supplemented with 20% FCS, 100U/ml penicillin, 100U/ml streptomycin, 
5mM Glutamine (EuroClone), 1mM sodium pyruvate (Gibco), 50 µM 2-
mercaptoethanol (Invitrogen) supplemented with 30% L929 cell-conditioned medium 
(L-cell) as a source of CSF-1. After 3 days, non-adherent cells were collected, and either 
cryogenically stored in macrophage growth medium containing 10% dimethyl 
sulphoxide (DMSO, Euroclone) or seeded at 105 cells/ml in bacteriological plates 
(Falcon), and grown for 5 days before use. Cells were then harvested using Versene 
(1:5000), centrifuged at 1200 rpm for 5 minutes and resuspended in macrophage growth 
medium. Freezing did not detectably modify the characteristics or the behavior of the 
macrophages that were obtained. All the results described here are from cells that had 
been cultured for no more than a total of 2 weeks.  
 
 
Expression and purification of recombinant proteins 
For the production of soluble uPAR mutants, semi-confluent CHO Flp-In cells stably 
transfected with the relevant expression vectors was washed in PBS and incubated for 
7–10 days in CHO protein-free medium (Sigma-Aldrich). The conditioned medium was 
used for in vitro binding assays without further purification. Recombinant Fc-fusion 
proteins were expressed in the same way, but were purified by standard Protein A 
affinity chromatography. The SMB used in adhesion and in vitro binding assays a fusion 
protein between VN (amino acid 1-66) and EGFP. It was purified from CHO cells 
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conditioned medium by mAb153 (anti-SMB) by affinity chromatography (Nicolai 
Sidenius, unpublished). 
 
Quantification of Fc-tagged mouse uPAR variants 
The concentration of Fc-tagged mouse uPAR variants in the conditioned medium of 
transfected CHO cells was measured by an ELISA-type assay using a polyclonal anti-
human Fc antibody (Sigma) for capturing and a monoclonal Eurobium-labeled anti-
human Fc antibody (Perkin Elmer) for detection by time-resolved fluorescence 
(DELFIA). A purified human IgG1 was used as standard. 
 
Cell Proliferation assay 
Cells were seeded at the concentration of 1.5x103/well on E-Plates (Roche) and their 
proliferation was monitored in real time by using the xCELLigence System  (Roche). 
The system measures electrical impedance across interdigitated microelectrodes 
integrated on the bottom of tissue culture E-Plates. The presence of the cells on top of 
the electrodes affect the local ionic environment at the electrode/solution interface, 
leading to an increase in the electrode impedance. The more cells are attached on the 
electrodes, the larger the increases in electrode impedance. The first impedance 
variations registered by the system are index of the initial cells spreading. After 2 h, 
when all the cells are attached to the plate, the registered impedance correlates 
exclusively with cell proliferation. Cell index was followed for 96 h and measurements 
taken every 15 minutes. The data are represented as the mean of 3 independent wells. 
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FACS analysis 
Cell surface expression of muPAR , muPAR D1 and muPAR D2D3 were analyzed by 
flow cytometry by using a polyclonal antibody directed against the full-length protein or 
monoclonal antibodies that recognize the D1 or D2D3 domains of muPAR. All these 
antibodies were used at the concentration of 5 µg/ml. Cells were stained with 
appropriate secondary Cy5-labelled antibody (diluted 1:50) or SAP-APC (diluted 1:800) 
and analyzed by flow cytometry (FACSCalibur; BD Biosciences).  Apoptosis was 
analyzed by staining the cells with Annexin V (1:50; Sigma-Aldrich) and Propidium 
Iodide (PI 50µg/ml in PBS; Sigma-Aldrich). 
   
Cell lysis and Western Blotting 
Cells were washed and lysed directly on the culture dish in ice-cold lysis buffer (25 mM 
Tris, pH 7.6, 150 mM NaCl, 1% Triton X-100, protease inhibitor cocktail [Complete-
EDTA-free], 1 mM PMSF, 1 mM EDTA, 1 mM NaF, and 1 mM Na3VO4) or in ice-cold 
RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, protease inhibitor cocktail [Complete-EDTA-free], 1 mM 
PMSF, 1 mM EDTA, 1 mM NaF, and 1 mM Na3VO4) followed by a brief sonication. 
The total protein content was determined using the DC-Protein assay (Bio-Rad 
Laboratories) with BSA as standard. Equal amounts of total protein were separated by 
SDS-PAGE and probed as indicated.  
 
Cell adhesion assay 
Cells were seeded at the concentration of 3 x 104/well on MaxiSorp 96-well plates 
(Nunc), coated with different substrates, and allowed to adhere in the presence or 
absence of pro-uPA (20 nM) and SMB (30 nM) for 30 min at 37°C. After washing, the 
 50 
adherent cells were fixed, stained with crystal violet, and quantified by measuring the 
absorbance at 540 nm. Coatings were as follows: poly-L-lysine 100 µg/ml (Engelbreth-
Holm-Swarm murine sarcoma), fibronectin 10 µg/ml (Roche), αvβ3 (Chemicon) 0,5 
µg/ml, purified VN, VNRAD, VN(1-66)RAD were all coated at 5 µg/ml. suPAR/Fc was 
coated 20 nM. pro-uPA was a kind gift of Jack Henkin Abbot. All measurements were 
done in triplicate, and the specific binding calculated by subtraction of the non-specific 
binding to BSA-coated wells.  
 
Binding assay of purified proteins 
In vitro binding assays were performed in black 96-well plates (Nunc MaxiSorp), 
coated with SMB/Fc (0,1 ml/well, 2 µg/ml in 0.05M phosphate buffer, pH 9.6) or 
mATF (0,1 ml/well, 1 µg/ml in 0.05M phosphate buffer, pH 9.6) over night at 4°C and 
blocked 1.15 ml of 2% BSA in PBS for 1 h. Subsequent incubations with smuPAR 
variants were performed with reagents diluted in dilution buffer (PBS containing 1% 
BSA) for 1 h at room temperature on a orbital shaker. Binding to SMB was induced by 
pre incubation with pro-uPA (100 nM). After extensive washing with PBS containing 
0.1% Tween 20 (PBS-T), the wells were probed for bound smuPAR with a Eu3+-labeled 
polyclonal anti-muPAR antibody (0.5 µg/ml) followed by the measurement of time-
resolved fluorescence. All measurements were done in triplicate, and the specific 
binding calculated by subtraction of the non-specific binding to BSA-coated wells.  
 
Differential Interference Contrast microscopy (DIC)  
Cells were plated at the concentration of 2 x 104/well on coverglass chambers (Lab-
TekII) and allowed to adhere for 24h. Cells were then fixed in 4% paraformaldehyde 
and rinsed with PBS (to maintain the requested difference of refractive indexes) and 
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subjected to DIC analysis. DIC imaging of cells was performed using an inverted 
microscope Olympus IX81. Cells were viewed through a high-aperture 60x objective 
lens (UIS2 60x TIRFM PlanApo N, NA 1.45; Olympus). Images were acquired using 
Hamamatsu Orca-ER digital camera with the software Metamorph 7.5.6.0.  For cell 
spreading assay the cell area of 50 cells/type was measured with ImageJ 1.42q. 
 
Phase contrast and time-lapse imaging 
Phase-contrast and time-lapse live-cell imaging was performed at 37°C, 5% CO2 
with an inverted microscope (IX80; Olympus) equipped with an incubation chamber 
(OKOlab) to control CO2 and temperature. Cells were plated in 12 well plates (Nunc) at 
the confluence of 1 x 105 cell/well. Time-lapse imaging was performed in serum-
containing growth medium. Cells were viewed through 10x (uPlan FLN 10X Ph1, N.A. 
0.30; Olympus) objective lenses and pictures were taken every 5 minutes for 5 h. The 
acquisition system includes a digital camera (Hamamatsu Orca-ER) and System Control 
Software Olympus ScanR. Adjustment of brightness/contrast, smoothening and 
sharpness of images was done using ImageJ 1.42q and always applied to the entire 
image. Cell migration speed was quantified with ImageJ 1.42q using the plug-in 
"manual tracking". In each experiment, 20 randomly chosen cells were tracked and their 
average migration speed throughout the experiment was calculated.  
 
Immunofluorescence Microscopy 
Cells were plated on 35mm dishes (Corning) and allowed to adhere overnight. Cells 
were washed in PBS, fixed in 4% parafolmaldehyde, permeabilized with 0.1% Triton 
X-100, 0.2% BSA in PBS, and blocked with 2% BSA in PBS. Cells were stained as 
indicated in the figures. EC were starved overnight before to proceed with the staining 
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in DMEM 1% BSA. Cell imaging was performed by using the full-motorized upright 
Olympus BX61 microscope. Cells were viewed through a 60x (uPlanApo 60x, N.A. 
1.45; Olympus), 20x (uPlanApo 20X, N.A. 0.70; Olympus) or 10x (UPlanFl 10X, N.A. 
0.30; Olympus) objective lens. Images were acquired using photometrics coolsnap EZ 
camera with the software Metamorph 7.5.6.0. Adjustment of brightness/contrast of 
images was done using ImajeJ 1.42q. 
 
Transgenic Mice 
Wt mice and mice lacking uPAR were used to obtain EC. Wt C57BL/6J (B6) mice were 
obtained from Charles River Laboratories. uPAR-/- mice were generated at Vlaams 
Interuniversitair Instituut (Leuven, Belgium) and inbred in B6 for 12 generations 
(Dewerchin et al., 1996). Mice were maintained in HEPA-filtered IVC units. All 
experiments were performed according to the guidelines for care and use of laboratory 
animals approved by the institutional ethical animal care committee. 
 
Xenograft Studies in Mice 
Anesthetized 8-weeks-old C.B-17/IcrCrl-scid-BR (Charles River Laboratories) were 
inoculated in the fourth mammary fat pad with 1 x 106 HEK293-GFP cells, suspended 
in 50 µl of 1:1 PBS and Matrigel (Sigma). Primary tumor growth was monitored every 
2 to 3 days by caliper. The tumor volume was estimated by the formula V = (length x 
width2) / 2. Mice were euthanized when the tumors were 2 cm3 (between 2 and 4 
months). Xenografts and lungs were recovered for analysis. 
Mice were maintained in HEPA-filtered IVC units. All experiments were 
performed according to the guidelines for care and use of laboratory animals approved 
by the institutional ethical animal care committee. 
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Results 
 
Identification and characterization of the VN binding epitope in 
murine uPAR (muPAR) 
 
The VN-binding epitope in human uPAR has been identified through a complete single-
site alanine scanning mutagenesis of either purified soluble human uPAR (suPAR) 
(Gardsvoll and Ploug, 2007) or full-length human uPAR expressed on HEK293 and 
CHO cells (Madsen et al., 2007). Five residues (W32, R58, I63, R91 and Y92) are 
critically involved. Given the high homology between the human and mouse receptors 
(Fig. 12), these residues were substituted with alanine by site-directed mutagenesis. The 
biological activity of the resulting receptor variants were then analyzed and compared to 
wild-type muPAR.  
 
 
 
 
 
Figure 12: Human uPAR vs Murine uPAR alignment. 
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The amino acid sequence of human uPAR (aa 1-322) has been aligned with the murine uPAR sequence 
(aa 1-315). Five residues (W32, R58, I63, R91 and Y92) constitute the VN binding site in huPAR. The 
matching amino acid sequence in the middle showed the high homology between the human and mouse 
receptors and how the residues involved the uPAR-VN interaction (reported in yellow) are fully 
conserved. 
 
 
For this purpose the generated muPAR variants and the muPAR wt were 
transfected in CHO Flp-In cells. The Flp-In system generates pools of isogenic 
transfectants carrying a single copy of the expression cassette, thus eliminating potential 
artifacts caused by clonal differences or heterogeneous expression levels. The correct 
expression of the mutants was checked by Western Blot analysis of total lysates (Fig. 
13). All the mutants showed a band at the expected molecular weight, as compared to 
the muPAR wild type. Some of the mutants (I63A, R58E, R58E+W32A) showed an 
upper band indicating SDS-resistant protein aggregates. 
 
 
 
 
 
Figure 13: WB analysis of CHO cells stably expressing murine uPAR. 
 
Cell expressing the receptor variants were lysed and muPAR expression was assayed by immunoblot. 
Representative western blot are shown.  
 
 
 
 
 
Expression of human uPAR in CHO cells resulted in a strong change in 
morphology and F-actin cytoskeleton (Madsen et al., 2007). The phase contrast analysis 
showed that parental CHO cells and cells expressing the mutants had comparable cell 
 55 
morphology, which was different from CHO cells expressing wild type muPAR. As an 
example we report the image of the muPARW32A mutant. The cells appear to grow in 
colonies while the muPAR wild type CHO cells are scattered (Fig. 14, upper panel). A 
further analysis of the morphology, by immunofluorescence microscopy, in which we 
stained for actin and vinculin, displayed the formation of protrusions and lamellipodia 
as well as the loss of stress fibers and focal adhesion dissociation only in muPAR wild 
type transfected cells (Fig. 14, lower panel). uPAR induced phenotype was completely 
reverted by the W32A and R92A point mutations, that disrupted the receptor binding to 
VN (Fig. 14, lower panel). Cells expressing the other receptor variants showed an 
intermediate phenotype.  
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Figure 14: mPAR-induced changes in cell morphology. 
 
CHO Flp-In cells (CHO) transfected with an empty vector (CHO/mock) or wild type muPAR 
(CHO/muPAR) and CHO Flp-In cells stably expressing uPARW32A mutant (CHO/muPAR-W32A) were 
analyzed by phase contrast microscopy (upper panels) or by confocal microscopy after fixation and 
staining with phalloidin-FITC and vinculin-Cy3 (lower panels). 
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The ability of the mutant receptors to promote cell adhesion to VN has been 
analyzed in cell adhesion assays to a modified VN in which the RGD sequence 
responsible for integrin binding has been mutated into RAD. As this modified VN does 
not support integrin dependent cell adhesion (Madsen et al., 2007) it allows for the 
direct quantification of uPAR dependent VN-adhesion. For comparison, integrin 
dependent adhesion to fibronectin (Fn, which is not a substrate for uPAR) was 
measured. All the different muPAR mutants failed to adhere to VN, maintaining a 
normal adhesion to Fn, demonstrating the effective loss of VN-binding to these 
receptors (Fig. 15). 
 
 
 
 
Figure 15: mPAR mutants in VN-binding epitope fail to adhere to VN. 
 
Adhesive properties of cells expressing muPAR mutants in VN-binding site, which completely fail to 
induce changes in CHO morphology. Cells were plated for 30 minutes on 96 well plates coated with FN 
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(10 µg/ml) and VN(1-66)RAD (5 µg/ml). Adherent cells were fixed and stained with crystal violet. Cell 
adhesion to muPAR wild type was set as 100% for each cell line. Data are expressed as mean ± s.e.m., 
number of independent experiments (n=3). 
 
 
 
 
The direct muPAR-VN interaction was also analyzed using purified proteins in 
an in vitro binding assay. We generated expression vectors encoding soluble variants of 
the mutant receptors fused to the constant region (Fc) of a human IgG molecule. These 
expression vectors were transfected into CHO cells and the recombinant proteins 
purified from the conditioned medium by protein-A affinity chromatography. Proteins 
concentration was then measured by ELISA-type assay. In vitro binding assays to 
immobilized VN and uPA were utilized to determine the binding constants of the 
different receptors for these interaction partners. While the uPA binding was not 
affected by the point mutations in muPAR (Fig. 16, left panel), the VN-binding was 
effectively abrogated by either W32A or R92A point mutation (Fig. 16, right panel).   
 
 
 
 
 
Figure 16: mPAR mutants in VN-binding epitope bind uPA. 
 
Soluble variants of muPAR mutant receptors were generated, expressed and tested for their ability to bind 
immobilized ATF (left panel) or SMB domain of VN (right panel) by in vitro binding assay. 
Representative IVB are shown. 
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Collectively, the data obtained from the analysis of the muPAR variants show 
that all the substitutions destroyed receptor binding to VN, without disturbing the 
binding to its natural ligand muPA. Moreover the receptors variants completely reverted 
the morphological phenotype resulting from the expression of muPAR in CHO cells. 
However, possible problems in the folding of the protein caused by some of the 
substitutions (see Fig. 13) reduced the number of the mutant candidates to the 
muPARW32A and the muPARR92A. We decided to use the muPARW32A for the next 
experiments, since R92 is an amino acid involved in the receptor cleavage and is a part 
of the uPAR chemotactic epitope (Fazioli et al., 1997). 
 
 
  Characterization of uPAR variants in HEK293 FlpIn cells 
 
 To determine uPAR-VN activities that may be important for cancer progression 
in vivo, we decided to express muPAR and muPARW32A receptors in HEK293 Flp-In 
cells. Although HEK-293 cells are not true cancer cells, due to the expression of 
adenoviral early region 1A, these cells are capable of forming tumors in 
immunodeficient mice (Graham et al., 1977). More important, these cells do not express 
both uPA and uPAR endogenously (Madsen et al., 2007). Besides the W32A receptor 
variant we decide to study another form of muPAR missing the whole D1 (muPARΔD1). 
This mutant receptor is not capable of both VN and uPA binding. In view of a possible 
progression of the xenografted tumors to form metastasis sites, HEK293 Flp-In cells 
were first transfected to express GFP, to better track macrometastasis, and then 
transfected with the empty vector (mock) or the three muPAR mutants (muPAR, 
muPARW32A and muPARΔD1). FACS analysis was performed to select a stable GFP 
expressing clone and to evaluate the receptors expression levels. All the receptor 
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variants and GFP were expressed at comparable levels (Fig. 17B and 17C). As 
expected, muPARΔD1 was not recognized by the antibody against the D1 of uPAR (Fig 
17D). 
 
 
 
 
 
 
Figure 17: muPAR variants are expressed at comparable levels in HEK293 cells. 
 
GFP and mutant receptors expression profiles were evaluated by FACS analysis. A: GFP expression level 
in HEK293 cells. Expression profiles of muPARW32A (blue) and muPARΔD1 (green), compared to muPAR 
(red) and mock cells (black), were detected by a polyclonal antibody against mouse uPAR (B), a specific 
anti-D2D3 antibody (C) and a monoclonal anti-D1 antibody (D). In violet parental cells. 
 
 
 
 
The comparable expression level will allow us to account for eventual 
differences to the functionality of our receptor variants and not to their amount on the 
cell surface.  
 61 
All the four cell lines (mock, muPAR, muPARW32A and muPARΔD1) were tested 
for their ability to adhere to immobilized VN and FN, in cell adhesion assay (Fig. 18). 
The wt receptor was able to promote cell binding to VN without disturbing the binding 
to Fn. Binding to VN was integrin-independent since the cells expressing muPAR 
adhered to VNRAD. Both muPARW32A and muPARΔD1 cells showed an impaired 
adhesion to immobilized VN and failed to adhere to VNRAD. The remaining VN-
adhesion observed in muPARW32A and muPARΔD1 expressing cells is integrin-mediated 
as it is comparable to the one observed in mock-transfected cells. 
 
 
 
 
Figure 18: muPAR variants failed to promote cell adhesion to VN. 
 
Adhesion assay: Mock, muPAR, muPARW32A and uPARΔD1 transfected HEK293 cells were plated for 30 
minutes on FN (10 µg/ml), VN (5 µg/ml) and VNRAD (5 µg/ml). Adherent cells were fixed and quantified 
by measuring GFP fluorescence on by ENVISION (PerkinElmer) plate reader. Cell adhesion to poly-D-
lysine was set as 100% for each cell line. Data are expressed as mean ± s.e.m., n=3. 
 
 
 
Moreover, uPAR expression doesn’t alter cell adhesion to the FN, as all the cells 
adhered to FN at comparable levels (Wei et al., 2005). 
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The observation that uPAR is overexpressed in human tumors and that the 
expression levels have strong prognostic value tentatively suggest that uPAR might be 
involved in tumor growth. Therefore we investigated the proliferating cell signal that 
may be triggered by uPAR-VN interaction. Figure 19 shows that the expression of 
muPAR on the cell surface enhanced cell proliferation. Importantly, cell proliferating 
signal is a consequence of the uPAR-VN interaction. In fact, the growth of the cell 
expressing the receptor variants, incapable of VN-binding, was comparable to the 
mock-transfected cells. 
 
 
 
 
Figure 19: uPAR-Vn interaction is required to promote cell proliferation. 
 
Dynamic monitoring of adherent cell proliferation. HEK293 muPAR (red), muPARW32A (blue), 
muPARDD1 (green) and mock (black) cells were seeded at 1500/well cell density on E-Plates. The cell 
growth curves were automatically recorded on the xCELLigence System in real time. Cell index was 
followed for 96 h (measurements every 15 minutes). Data represent the mean of 3 independent wells. For 
clarity SD is not shown. 
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To further investigate the proliferative signal transduction induced by uPAR-VN 
interaction we assayed the ERK1/2 activation by Western blot. Serum starved 
HEK293/muPAR cells displayed higher level of ERK1/2 phosphorylation, compared to 
mock transfected cells. Activation of ERK1/2 in mock and the receptor variants 
expressing cells was comparable (Fig. 20). 
Taken together these results demonstrated that uPAR-VN interaction triggers 
MAPK activation that is presumably responsible for the differences in cell growth 
observed in the proliferation assay. 
 
 
 
Figure 20: uPAR-VN interaction induces ERK1/2 activation. 
 
Immunoblot analysis of ERK1/2 phosphorylation upon uPAR-VN interaction. Western blot (upper panel) 
and densitometric analysis (lower panel) are shown. Cells were serum starved for 4 hours prior to lysis. 
Blots were first probed for phosphorylated ERK1/2 (top blot) then stripped and reprobed for total ERK1/2 
(bottom blot). The graph shows the mean ± s.e.m. increase in the ratio between phosphorylated and total 
ERK1/2 (n=5). Ratio of muPAR wild type (WT) expressing cells was set as 100%. Representative 
western blot are shown. 
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HEK293 cells are poorly adherent cells. uPAR-VN interaction could increase 
the integrins binding to the ECM (Madsen et al., 2007), thus preventing cell apoptosis 
induced by loss of anchorage, a phenomenon also known as anoikis. After initiation of 
apoptosis, most cell types translocate the membrane phospholipid PS from the inner 
surface of the plasma membrane to the outside. PS can be detected by staining with 
Annexin V that binds naturally to PS. During programmed cell death, PS externalization 
precedes membrane bleb formation and DNA fragmentation. Figure 21 shows Annexin 
V staining in conjugation with PI staining performed in all four cell lines. 
 
 
 
Figure 21: muPAR expression preserves cells from apoptosis. 
 
Contour diagram of Annexin V/PI flow cytometry: Lower left quadrants of each panels show the viable 
cells, which exclude PI and are negative for Annexin V binding. The upper right quadrants contain the 
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non-viable, necrotic cells, positive for PI uptake and Annexin V binding. The lower right quadrants 
represent the apoptotic cells, PI negative and Annexin V positive, demonstrating cytoplasmic membrane 
integrity. One representative experiment out of three is shown. 
 
Expression of Wt muPAR on the cell surface prevented HEK293 cells from apoptosis. 
This phenomenon did not happen in absence of uPAR-VN interaction. The loss of cell 
VN-binding in HEK293muPARW32A, in fact, induce a shift in Annexin fluorescence 
intensity. Interestingly, muPARW32A expressing cells showed a slight increase in the 
Annexin V staining respect to the control cells. On the contrary, the Annexin V/PI 
staining of HEK293muPARΔD1 and mock cells were comparable (Fig. 21). Further 
experiment are needed to clarify the difference observed in this apoptosis assay, in 
particular among the muPARW32A, muPARΔD1 and mock transfected cells. 
As previously reported, uPAR-VN interaction is responsible for cell morphology 
changes and cell migration (Madsen et al., 2007). 
To monitor the morphology changes upon uPAR-VN interaction, we quantified 
the area of individual cells through DIC microscopy and image analysis. When grown 
under serum containing conditions the expression of muPAR, but not of uPARW32A or 
muPARΔD1, resulted in increased cell spreading (~2.5-fold) as compared to mock-
transfected cells (Fig. 22). To see whether these uPAR-VN induced morphology 
chances could result in different cell motility we performed migration assays, testing the 
migratory capacity of uPAR receptor variants. As expected, muPAR expression resulted 
in an increased migration speed compared to the other cells (Fig. 23). The increased cell 
spreading observed in muPAR expressing cells translated into enhanced cell migration. 
 Consistently the lack of uPAR-VN interaction resulted in a migration speed 
comparable to mock transfected cells. 
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Figure 22: Increased cell-matrix contact area upon muPAR mediated VN adhesion.  
 
Cell-matrix contact area was quantified by cell spreading assay: Sparse cells were grown for 24h. After 
fixation DIC images were taken and cell areas were quantified using ImageJ software. Columns are mean 
± 95% confidence interval, n=50, two independent experiments. Average do not represents the area of 
one single cell. 
 
 
 
 
 
Figure 23: muPAR-VN interaction promotes cell migration.  
 
HEK293/mock, HEK293/muPAR, HEK293/muPARW32A and muPARΔD1 cells were seeded at sparse 
conditions and allowed to adhere for 24h. Cells were monitored for 5h (1 frame every 5 min.) by phase-
contrast time-lapse recordings. Cell migration speed was quantified by manual cell tracking using ImageJ 
software. Columns are mean ± 95% confidence interval, n=25, two independent experiments.  
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We further analyzed the signal transduction pathway that could be responsible 
for enhanced cell spreading and migration. Thus the phosphorylation of p130Cas, 
involved in cell spreading and migration, was assayed through immune blotting and 
quantified with densitometry. Serum starved muPAR cells displayed an increased 
p130Cas substrate domain (SD) phosphorylation, compared to mock and receptor 
variants transfected cells (Fig. 24).  
 
 
 
Figure 24: muPAR-VN interaction induces P130Cas phosphorylation. 
 
muPAR, muPARW32A, muPARΔD1 and mock HEK293 cells were serum starved for 4 hours and prior to 
lysis. Blots were first probed for phosphorylated p130Cas (top blot) then stripped and reprobed for 
vinculin (bottom blot). The graph shows the mean ± s.e.m. in the ratio between phosphorylated and total 
protein (n=5). Ratio of muPAR wild type (WT) untreated cells was set as 100%. Representative western 
blots are shown. 
 
 
As reported by other studies, P130Cas phosphorylation triggers lamellipodia 
protrusion and cell migration through the upregulation of Rac1 activity (Smith et al., 
2008). 
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In summary, these data show that the ability of uPAR to induce changes in 
HEK293 cells morphology is a two-step process in which uPAR, through the direct 
interaction with VN triggers cell attachment to the matrix. Consequently this initial 
adhesion is followed by engagement of integrins with matrix VN, triggering changes in 
cell morphology and migration.  
 
 
HEK293 tumorigenesis in SCID mice 
 
The differences observed in the in vitro assays could suggest that uPAR-VN interaction 
may modulate tumor growth and metastasis dissemination in a xenotransplanted in vivo 
system. 
To test this possibility, all the four cell lines, previously characterized, were 
inoculated into mammary fat pads in immunodeficient SCID mice. Tumor growth was 
followed by caliper measurements until the primary tumor mass reached a size of about 
2 cm3. Each cell line formed palpable tumours independently of the construct expressed. 
Importantly, muPAR expression induced an earlier formation of the primary tumor 
mass (about 1 week earlier) (Fig. 25, left panel) respect to mock transfected cells, in 
accordance with the enhanced proliferative capability of these cells. The observed 
effects are specifically related to ability of uPAR in inducing VN adhesion. 
Consistently, muPARW32A expression, a mutant defective in VN-binding, significantly 
slowed down the tumor growth. Interestingly, tumor mass formed by 
HEK293muPARW32A showed an impaired growth even when compared to mock cells 
(Fig. 25, right panel). No changes in the tumor formation and growth rate were induced 
by the expression of muPARΔD1, defective in both VN and uPA binding, if compared to 
 69 
mock transfected cells (Fig. 25). These data indicates that uPAR-VN interaction 
accelerates the process of tumor formation.  
The fact that muPARW32A expressing cells display an impaired tumor formation, respect 
to mock transfected cells, could indicate uPA to be a negative regulator of cancer 
growth rate. Consistently, cells expressing a receptor variant, in which the removed-D1 
prevents uPA interaction, display the same growth rate of mock cells. 
 
 
 
 
 
 
Figure 25: Effect of uPAR-VN interaction on xenograft growth rate in SCID mice. 
 
Primary tumor growth and size were monitored using calipers until the size of tumor reached a maximum 
diameter of 2 cm. Number of mice used for each cell line are indicated (n). The curves plot the percent of 
tumor free mice (left panel) or the percent of tumor size ≥ 2 cm3 (right panel) as a function of time.  
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HEK293 cells-induced tumors do not form macro-metastasis 
 
Mice were euthanized when the primary tumor reached 2 cm3. In no case we observed 
changes in animal behavior to indicate discomfort.  Xenografts and lungs were 
recovered and examined using a fluorescent stereomicroscope.  
 
 
 
 
Figure 26: Lungs of HEK293 cells inoculated mice doesn’t present metastasis foci. 
 
Xenografts and lungs were collected from euthanized mice, fixed in 4% PFA 24 h and analyzed under 
fluorescent microscope. Representative images of lungs front and back views (upper panel) and of 
xenografted primary tumor (lower panel) are shown.  
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No metastasis were identified by the presence of green-fluorescent foci on the 
surface of the lungs. An example of lungs appearance is shown in figure 26, upper 
panel. The absence of green-fluorescent foci was not due to a loss of the GFP 
expression within the cells, as the excised tumor retains the fluorescence (Fig. 26, lower 
panel). However these results are not conclusive and may not exclude the presence of 
micrometastasis all over the body. Further experiments will be needed in order to clarify 
the role of uPAR-VN interaction in metastasis formation. 
 
 
Mechanisms underlying the function of the uPAR-VN interaction in 
vivo 
 
Although the function of the uPAR/VN-interaction in cell adhesion and migration has 
been extensively documented in vitro, it is not clear if and how this interaction may 
occur in vivo. It is straightforward to speculate that over-expression of uPAR by cancer 
cells may empower their migration/invasion in a VN-containing matrix, possibly in the 
tumor stroma, as demonstrated by the dramatic changes in cell migration on serum 
coated surfaces documented above. We have however decided to experimentally 
address also an alternative mechanism, which may explain a possible functional role the 
uPAR/VN-interaction in vivo. The rationale behind these experiments derives from the 
fact that the binding sites for uPAR and integrins in VN are non-overlapping, thus 
possibly allowing for the contemporary binding of both receptors. If the two receptor 
types are expressed on different cell types (i.e. uPAR on activated leukocytes and VN-
integrin on endothelial cells) VN may promote cell-to-cell adhesion in processes such as 
leukocyte or cancer cell extravasation. 
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To establish whether uPAR and integrins may bind contemporarily to a single 
molecule of VN we conducted in vitro binding experiments (IVB) using purified 
components. In these experiments purified integrin (αVβ3) was immobilized and 
subsequently incubated with the monomeric SMB-RGD-domain of VN (which includes 
the specific uPAR and integrin binding sites) and soluble uPAR in the presence or 
absence of uPA (Fig. 27). The absence of absence of SMB and/or uPA resulted in no 
suPAR-integrin interaction, demonstrating that uPAR does not bind directly to αVβ3. On 
the contrary, the presence of both uPA and SMB-RGD-domain of VN promoted the 
binding of suPAR to the integrin. These findings suggest that VN acts as a bridge 
connecting uPAR to integrin. In particular integrins engage VN in the specific RGD 
motif while suPAR, occupied by uPA, interacts at the same time with the SMB domain.  
 
 
Figure 27: SMB- and uPA-dependent suPAR binding to αVβ3. 
 
Binding of purified soluble uPAR to immobilized αvβ3-integrin. 96-well plates were coated with purified 
αvβ3-integrin, blocked with BSA, and incubated with a GFP-tagged SMB-domain. After washing away 
unbound SMB the wells were incubated with increasing concentrations of soluble uPAR (uPAR/Fc) in 
the presence or absence of pro-uPA (100 nM). Non-specific binding was determined in BSA-coated wells 
treated in the same way. 
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The ability of VN to connect uPAR molecule to a cell expressing αVβ3 integrin 
was tested in complementary experiments by adhesion assay. In these experiments 
purified suPAR was immobilized and subsequently incubated with the monomeric SMB 
domain of VN. The adhesion of cells expressing αVβ3 integrin was analyzed in presence 
or absence of uPA. In a first experiment, the adhesion of Rat smooth muscle cells 
(RSMC) was assayed. As for the IVB, the obtained results demonstrated that both SMB 
and uPA are required for uPAR/integrin interaction and, more importantly, that this 
“bridging” effect of the SMB is not mediated by direct uPAR/integrin interactions (Fig. 
28).  
 
 
 
 
 
Figure 28: β3 mediated RSMC adhesion to uPAR/uPA/VN-complexes. 
 
Adhesion of αVβ3 expressing rat smooth muscle cells (RSMC) to immobilized suPAR. 96-well plates 
were coated with suPAR and incubated with SMB (30 nM) and uPA (20 nM)  as indicated. Cells were 
allowed to adhere for 30 minutes and quantified by crystal violet staining. Background adhesion was 
determined using BSA-coated wells. The extend of adhesion is presented as percentage of direct adhesion 
to an immobilized SMB-domain. 
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These data were confirmed by a second experiment where adhesion of HEK293 
cells expressing β3 integrin (β3WT), activated by manganese (β3WT+Mn2+), or a 
constitutively activated β3 integrin (β3303T) (Luo et al., 2003) were used in replacement 
of RSMC. Importantly the endogenous array of integrin receptors expressed by 
HEK293 cells is not proficient in inducing a detectable adhesion in this kind of assay 
(Fig. 29). Indeed mock transfected cells adhered poorly to VN in an αvβ5 dependent 
fashion (Madsen et al., 2007). 
 
 
 
 
Figure 29: β3 mediated cell adhesion to uPAR/uPA/VN-complexes. 
 
Adhesion assay of HEK293 cells overexpressing β3 integrin, β3 integrin activated by Mn2+ or β3303T 
activated integrin to immobilized suPAR (20 nM), in presence/absence of uPA (20 nM) and SMB (30 
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nM). Adherent cells were fixed and stained with crystal violet. Cell adhesion to poly-D-lysine was set as 
100% for each cell line. Data are expressed as mean ± s.e.m., n=3. HEK293 cells over expressing β3 and 
β3303T integrin were generated in the laboratory (Sarra Ferraris et al., unpublished). 
 
Taken together these data strongly support the notion that VN may promote 
adhesion between cells expressing uPAR and VN-integrins, suggesting a possible role 
of the uPAR/VN-interaction also in cell-to-cell adhesion. 
An unexpected result was the finding that VN could also connect two uPAR 
molecules. 
 
 
 
 
Figure 30: uPAR-mediated cell adhesion to uPAR/uPA/VN-complexes. 
 
Adhesion assay of HEK293 cells expressing human uPAR to immobilized suPAR, (20 nM) in 
presence/absence of uPA (20 nM) and SMB (30 nM). Adherent cells were fixed and stained with crystal 
violet. Cell adhesion to poly-D-lysine was set as 100% for each cell line. Data are expressed as mean ± 
s.e.m., n=3. 
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In the performed experiment uPAR expressing HEK293 cells were allowed to 
adhere to immobilized suPAR, in presence or absence of SMB/uPA. Interestingly, SMB 
promoted adhesion of cells expressing uPAR to the immobilized suPAR incubated with 
both SMB and uPA (Fig. 30). The lack of either uPA or SMB resulted in no cell 
adhesion to immobilized suPAR. These findings could suggest that the SMB domain of 
VN molecule could be engaged by at least two uPAR molecules at the same time. 
 
 
Derivation and characterization of endothelial cells and Bone marrow-
derived macrophages from uPAR Wt and null mice 
 
With the future aim of investigate the “bridging” capacity of VN to connect different 
cell types in a cell-to-cell adhesion assay, we derived macrophages and endothelial cells 
(EC) from uPAR Wt and knockout mice. Macrophages, which are in direct and constant 
contact with VN and are known to express high levels of uPAR when activated, interact 
indeed with EC expressing αvβ3 integrin, to reach the site of infection. Thus this could 
be an optimal system to test the physiological relevance of the VN “bridging” effect 
between these two cell types.  
Endothelial cells were derived from lungs of two months old uPAR Wt and null 
mice and developed by direct infection with Polyoma middle T (PmT). To verify the 
purity of the endothelial population, the derived cells were stained for PECAM and VE-
cadherin by immunofluorescence. PECAM (platelet endothelial cell adhesion molecule) 
is an adhesion molecule, expressed also in leukocytes and platelets (Dejana, 2004), that 
belongs to the immunoglobulin family. VE-cadherin (vascular endothelial cadherin) is a 
specific endothelial cell-to-cell adhesion molecule. uPAR Wt and the uPAR Ko derived 
 77 
EC were positive for both the endothelial markers, strongly suggesting that we derived a 
pure endothelium (Fig. 31).  Moreover, Figure 32 shows that uPAR Wt and uPAR Ko 
lung endothelial cells expressed the same amount of VE-cadherin. 
 
 
 
 
 
Figure 31: Immunofluorescence of lung-derived EC from uPAR+/+ and uPAR-/- mice. 
 
Lung endothelial cells from uPAR+/+ (upper panel) and uPAR-/- mice (lower panel) were plated on 
35mm plates pre-coated with 0.1% gelatin, let in culture for 2 days and starved overnight before fixation. 
Cells were then stained for PECAM (red) and VE-cadherin (green). The nuclear dye DAPI (blue) was 
used to counterstain cells. Representative images are shown. 
 
 
 78 
 
Figure 32: Western Blot analysis of EC derived from uPAR+/+ and uPAR-/- mice. 
 
EC were cultured for two days and starved overnight before cell lysis and Western blot. Blots were 
probed for the endothelial cell-to-cell adhesion molecule VE-cadherin (top blot) and for uPAR (middle 
blot) then stripped and reprobed for vinculin as loading control (bottom blot). Two representative EC 
clones (cl) are shown for each genotype.  
 
 
 
 
 
 
 
 
Figure 33: FACS analysis of BMM from uPAR+/+ and uPAR-/- mice. 
 
Expression of macrophages specific antigen F4/80 (Y axis) and of uPAR (X axis) were evaluated by 
FACS analysis. A: BMM from uPAR -/- mice. B: BMM from uPAR+/+ mice. 
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Macrophages were derived from the bone marrow of uPAR+/+ and uPAR-/- 
mice. 
The absence of uPAR didn’t compromised macrophages differentiation. In fact, all the 
bone marrow-derived cells expressed the macrophage antigen F4/80 (Fig. 33).  
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Discussion 
 
VN-binding epitope in mouse uPAR 
 
Established models regarding the function of uPAR cancer implicate its activity as a 
protease receptor. Indeed, proteases activation and ECM remodeling are required in cell 
migration in vivo. However a secondary function of uPAR in orchestrating intracellular 
signaling, independently of its proteolytic activity has been suggested by a growing 
number of evidences. Considering the complexity of a tumor scenario, the proteolytic 
and non-proteolytic function of uPAR may synergistically cooperate in the process of 
tumor progression.  
It has been demonstrated that the direct interaction between cell surface uPAR 
and the extra-cellular protein VN is required for the ability of uPAR to modulate 
changes in cell morphology and migration (Madsen et al., 2007). Moreover, it has been 
extensively documented that signal transduction initiated by uPAR-VN interaction 
occurs through the regulation of integrin signaling (Kjoller and Hall, 2001; Smith et al., 
2008) and it does not involve a direct interaction between uPAR and integrins (Madsen 
et al., 2007). 
Nevertheless the biological relevance of uPAR-VN interaction in cancer 
progression has never been investigated. In order to define the role of uPAR-VN 
interaction in this process we generated a simple cell system that will be finally used in 
xenotransplanted tumor model. This cell system will take advantage of the previous 
extensive characterization of the interaction interface between uPAR and VN. Indeed 
VN-binding epitope in human uPAR has been previously identified (Gardsvoll and 
Ploug, 2007; Madsen et al., 2007). It is constituted of 3 residues (W32, R58A, I63A) of 
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the D1 and 2 residues (R91, Y92) localized in the linker region between D1 and D2. 
Given the fully conservation of the VN binding epitope of uPAR in the mouse system, 
we introduced corresponding mutations by site directed mutagenesis in the murine 
receptor, which resulted in impaired uPAR-VN interaction. All the mutant receptors 
resulted to impair cell attachment to VN in an integrin-independent fashion, preserving 
the ability to bind to uPAR natural ligand uPA. More importantly, the absent uPAR-VN 
interaction that characterized all the receptor variants abolished those morphological 
chances such as loss of stress fibers and an accelerate FA turnover observed in the Wt 
receptor (muPAR). These results are completely in agreement with the published data 
obtained from the characterization of VN-binding epitope in human uPAR (Madsen et 
al., 2007).  
In addition, uPAR has been reported to modulate integrin-mediated adhesion by 
a direct interaction (Wei et al., 2005). However, in our system, uPAR expression didn’t 
result in an increased integrin-mediated VN or FN adhesion. This difference could be 
due to the different cell line used by Wei et al. in their cell adhesion assays. In fact, the 
authors use a cancer cell line that could express different levels of uPAR as well as 
uPAR-interacting factors respect to HEK293 Flp-In cells. It is also known that many 
cancer cells produce ECM factors that could have an effect in experiments performed 
on purified substrates. Moreover the different experimental conditions such as extensive 
washing of the cells, cell-adhesion timing, the different media used and the solution 
used to block the coated plated could influence the output of the experiments. 
Importantly, in Wei et al. paper cell adhesion is not quantified and normalized but it is 
shown as representative picture of stained plates. 
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uPAR and cell migration 
 
Cell migration is the locomotion of cell over an ECM substratum. It involves extension 
at the leading edge and retraction at the trailing edge of the cell. Extension of the 
leading edge of the cell is associated with cell adhesion, which is induced by integrin 
binding to ECM ligands, triggering the anchoring of new polymerized actin to the 
integrins to form focal adhesion. Many studies have implicated uPAR as an important 
regulator in cell motility. Several studies support the uPA dependency of uPAR-induced 
migration. In fact, antibody against uPA inhibited migration of some cell types, while 
ATF stimulated migration in a proteolysis independent fashion (Andreasen et al., 1997). 
Other studies emphasize how uPAR-induced migration is uPA-independent. Indeed, 
expression of uPAR in Swiss 3T3 cells enhances cell migration, depending on the 
interaction between uPAR and VN (Kjoller and Hall, 2001). The effect of uPA on cell 
migration may be caused by its proteolytic function in vivo. Indeed proteolytic 
degradation of ECM is an hallmark of mesenchymal cell-migration (Friedl, 2004). 
Moreover, uPAR, upon uPA interaction increases its affinity to VN (Sidenius et al., 
2002). As a consequence, cell lines expressing low uPAR levels will be dependent on 
uPA interaction for efficient VN adhesion whereas high levels of uPAR expression is 
sufficient to directly mediate VN cell adhesion independently of uPA. 
In our in vitro studies, muPAR overexpression resulted in enhanced cell 
adhesion and migration without requiring uPA interaction. This effect was lost in the 
absence of uPAR-VN interaction, as cell contact area and migration of 
HEK293muPARW32A and HEK293ΔD1 were comparable to mock counterparts. 
In agreement with previous studies (Kjoller and Hall, 2001; Smith et al., 2008), 
uPAR-VN interaction promotes P130Cas phosphorylation, leading to increased Rac1 
activity that promotes ruffling and lamellipodia protrusion. In this way the enhanced 
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P130Cas phosphorylation that we observed upon uPAR-VN interaction can be linked to 
the pro-migratory phenotype that characterizes muPAR Wt expressing cells. 
 
The uPAR-system and proliferation/apoptosis 
 
The ability of tumor cells to migrate and invade through the basement membrane into 
surrounding tissues is one of the essential hallmarks of cancer and a prerequisite for 
both local tumor progression and metastasis. But transformation, migration and invasion 
of tumor cells requires their resistance to the endogenous death program once the cell 
has detached from the primary tumor tissue. Indeed, many cell types derived from 
human malignancies, such as gastric cancer, breast cancer, colon cancer, osteosarcomas, 
and lung cancer, are resistant to anoikis. 
Recent studies demonstrate a close correlation between the uPA/uPAR-system and cell 
sensitivity to programmed cell death. Yanamandra and coworkers reported that SNB19 
glioblastoma cells expressing antisense uPAR constructs are less invasive than parental 
cells when injected in vivo. They found that in vivo inhibition of tumor growth is 
associated with activation of caspase-9 and subsequent apoptosis (Yanamandra et al., 
2000).  
Differences in cell growth can be accounted to different processes: increased cell 
proliferation or decreased apoptosis. Accordingly to previous findings, our data show 
that muPAR expression in HEK293 cells prevent programmed cell death.  In parallel 
the proliferation assay showed an increased growth rate upon uPAR-VN interaction. On 
the other hand, cells expressing the muPARW32A are not protected from apoptosis and 
showed a growth rate comparable to the mock-transfected cells. 
The lack of uPAR-VN interaction resulted in a diminished cell proliferation and 
an enhanced apoptosis. 
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The decrease of apoptosis/increased growth rate correlates with enhanced 
ERK1/2 activation in muPAR Wt expressing cells. Importantly, the mitogenic signal 
downstream of uPAR is dependent on its interaction with VN. Indeed 
HEK293muPARW32A and HEK293ΔD1 cells do not displayed major upregulation in 
MAPK activation respect to mock-transfected cells. Consistently, MAPK signaling 
rules the transcriptional program that regulates DNA synthesis and contrasts apoptotic 
processes (Hildenbrand et al., 2008).  These evidences could also explain the behavior 
of the cells injected into mice in our xenograft model. 
 
Importance of uPAR-VN interaction in cancer 
 
 
Several molecular components involved in ECM degradation are strong 
prognostic markers in several types of cancer, and inhibition of extracellular proteolysis 
is recognized as a valid approach to cancer therapy. However, the proteases have many 
functions in the normal organism. It is therefore inevitable that efficient inhibition will 
have toxic effects. Moreover the functional overlap between different proteases system 
means that combination of inhibitors must be used in order to obtain efficient anti-
invasive therapy. This combination will additionally increase the toxicity.  
Numerous reports documented the involvement of uPAR and uPA levels in 
cancer. However the loss of uPAR in the host did not prevent tumor growth (Bajou et 
al., 2001), but the use of antagonists of uPA or uPAR prevented growth invasiveness 
and metastasis of tumors (Crowley et al., 1993; Lakka et al., 2001; Min et al., 1996).  
These evidences suggest that in tumor scenario a major role is played by uPAR 
expressed by the tumor cells and not by the host, although uPAR expression has been 
found also in tumor-associated macrophages (see introduction). In this study we 
confirmed the importance of uPAR expression on cancer cells to induce and accelerate 
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tumor formation, as mice xenografted with muPAR expressing cells showed a 
premature primary tumor formation respect to mock injected mice. More important we 
found that uPAR-effect on cancer cells can be impaired by blocking its interaction with 
the ECM protein VN. Indeed the complete depletion of D1 (involved in VN and uPA 
binding (Sidenius and Blasi, 2000) or the specific mutation of the VN binding epitope 
abolished the uPAR-mediated effect on tumor formation. Surprisingly, an uPAR variant 
(muPARW32A) that can only interact with uPA, negatively regulated tumor formation, 
indicating that uPAR-uPA interaction could impaired cancer cell proliferation.  
The effect that uPAR exerts on cancer cell proliferation was not observed in a 
similar study by Jo et al. (Jo et al., 2009). The authors transfected HEK293 cells 
expressing either human or mouse uPAR to express GFP and injected these cells in the 
fourth mammary fat pad of SCID mice.  Tumor growth measurement and time of mice 
euthanization were similar to the ones we described. They found that uPAR expression 
was not associated with a significant change in the growth rate of the primary tumor. 
Moreover both human and mouse uPAR promoted lung metastasis (Fig. 8). Because of 
the activity of human uPAR they conclude uPAR-promoting cancer metastasis is uPA-
independent.  
Although the uPAR-uPA interaction shows species specificity, the binding 
between the mouse uPA and the human receptor occurs just with a lower affinity. The 
uPA concentration in a living system could be high enough to compensate the impaired 
affinity between the receptor and ligand of different species. 
 A possible explanation for the discrepancy between our and Jo et al. results can be 
found in the different cell line and method of transfection used. Jo et al. used HEK293 
cells, transfected to express uPAR or the empty vector and subjected to single cell 
cloning. These cells were further transfected to express GFP and again subjected to 
single cell cloning. Differently, we used HEK293 Flp-In cells that have been first 
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transfected to express GFP and subjected to single cell cloning.  The selected GFP clone 
was further transfected with muPAR variants or empty vector, taken advantage of the 
Flp-In system that generates pools of isogenic transfectants carrying a single copy of the 
expression cassette, thus by eliminating potential artifacts caused by clonal differences 
or heterogeneous expression levels.  The absence of metastasis foci in our mice could be 
also due to the no metastatic potential of the GFP clone that we have selected.
 Additionally, our results show that uPA can be a negative regulator of tumor 
growth. Indeed cell expressing muPARW32A, that cannot interact with VN but retains 
uPA-binding activity, displayed an impaired growth rate respect to mock transfected 
cells. Consistently cells expressing muPARΔD1, in which the interaction with both VN 
and uPA is blunted, behaved like uPAR-negative cells. The negative role of uPA in 
tumor cell growth should be clarified by further experiments, maybe taking advantage 
of a mutant form of uPAR where just uPA binding is impaired. However, the generation 
of this mutant variant is quite difficult, since uPA-binding interest all the three domains 
of uPAR. 
  
Role of uPAR-VN interaction in Inflammation and cancer 
 
 
Substantial evidences suggest a role of uPAR in leukocyte recruitment. uPAR-deficient 
mice showed an impaired neutrophils recruitment in response to Pulmonary 
Pseudomonas aeruginosa infection (Fig. 10) (Gyetko et al., 2000). Thioglycolate-
elicited leukocyte recruitment to the peritoneal cavity is reduced in uPAR-deficient 
mice (May et al., 1998). In addition, macrophages from uPAR-deficient mice showed a 
defective adhesion to pulmonary capillary endothelial cell monolayers respect to Wt 
counterpart (Gyetko et al., 2000). In all these studies the absence of uPAR did not 
abrogate completely leukocyte recruitment; possibly because uPAR is a modulator of β2 
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integrin (Cao et al., 1995) and β2 integrin can still engage its specific ligands even in 
absence of uPAR. Consistently, Wt mice had diminished neutrophil recruitment to the 
lung when an anti-CD11b mAb is given before inoculation with the pathogen, while 
recruitment of uPAR-/- neutrophils is unaffected (Gyetko et al., 2000). Probably the 
combined blockage of both uPAR and β2 integrin would result in complete depletion of 
leukocytes migratory capacity.  
Up to now there are no studies investigating the role of uPAR-VN interaction in 
inflammation. We demonstrated that uPA-VN could act as a bridge, connecting uPAR 
to purified αvβ3 integrin protein or to cell expressing αvβ3 integrin. These results 
strongly support the idea that the crosstalk between uPAR and VN-αvβ3 could play a 
role in leukocytes recruitment in the site of infection and, in particular, in intravasation 
and extravasation processes. Indeed uPAR is expressed on activated leukocytes and 
αvβ3 integrin is expressed on endothelial cells. A cell to cell adhesion assay between 
macrophages and endothelial cells will help us to test our hypothesis, with particular 
attention to the VN-bridge function. For this purpose macrophages and endothelial cells 
were derived from uPAR+/+ and uPAR-/- mice. More in particular, Macrophages were 
derived from mouse bone marrow, while endothelial cells from mouse lungs. Both Wt 
and uPAR Ko macrophages showed no problem in their differentiation. A better 
morphological characterization of macrophages and endothelial cells is required in view 
of future experiments.  
Madsen et al. demonstrated that VN-uPAR interaction provides the key to 
induce adhesion and cell migration (Madsen et al., 2007). Is our thought that cancer 
cells could mimic the leukocyte capacity to over-express uPAR to enter the tumor blood 
vessels and to reach the site of metastatization. After vascular leakage at the site of 
tumor, in fact, VN could get in contact with cancer cells expressing uPAR on the cell 
surface, thus promoting such morphological chances responsible for cell migration. 
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Interestingly, VN deposition was found in several tumor sites (Gladson and Cheresh, 
1991; Gladson et al., 1995; Maenpaa et al., 1997). Consequently, uPAR expressed by 
cancer cells could interact with VN associated to αvβ3 integrin of endothelial cell to exit 
the blood vessel and reach the site of metastasis formation. To study the role of uPAR-
VN interaction in cancer cell invasion and extravasation it is our intention to perform 
trans-endothelial migration of uPAR expressing tumor cell lines. 
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FUTURE PERSPECTIVES 
 
 
uPAR appears to be strongly upregulated in many inflammatory diseases and in 
practically all types of cancer. Stromal cells and cancer cells in the invasive front of 
human tumors often exhibit a specific and high expression of uPAR, pointing to an 
important role during tumor dissemination. In the context of cancer dissemination, 
proteolytic remodeling of the ECM is often regarded as an advantage for invasive 
tumors although proteolysis-independent cancer invasion have been observed by the 
power of cancer cells to interconvert from a collective or mesenchymal mode of 
motility to an amoeboid type of migration surpassing the need of ECM degradation. 
Proteolytic degradation of the ECM can be executed by cancer and stromal cells, such 
as tumor associated macrophages and fibroblasts. The ability of uPAR to initiate 
extracellular proteolysis and to launch a broad range of signals regulating cell migration 
and proliferation places uPAR as a promising therapeutic target for tumor prevention.  
The proteolytic function of uPAR during cancer progression has to some extent 
been evaluated in mice while the non-proteolytic function scarcely has been assessed. 
The newly characterized binding-interface between mouse uPAR and VN now permits 
the evaluation of this interaction to be scrutinized in more details in vivo. Of particular 
interest is the interplay between uPAR and VN during disease progression and during 
activation of the innate immune system. It is of great interest to establish whether VN 
incorporation into specific niches supports retention and recruitment of uPAR 
expressing cancer cells, immune cells and stem cells. The ability of uPAR-VN to fire up 
the activation of Rac1 and ERK1/2 in vitro may also have great impact on cancer cell 
invasion and growth in vivo.  
It is becoming clear that unraveling the molecular mechanism(s) underlying 
non-proteolytic uPAR signaling is of fundamental importance. However, the non-
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proteolytic function of uPAR has already received much “in vitro attention” and with 
that in mind it is now imperative to re-evaluate the available set of information through 
experimental in vivo enquiries. Further studies taking advantage of cancer cell lines, 
modulated for uPAR interaction with different binding proteins, in a mouse system 
were uPAR, uPA, VN, or integrin has been knocked-out will provide fundamental 
information regarding the uPAR interaction network and its in vivo implication(s).  
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Appendix A 
 
Oligonucleotides used for cloning (5’-3’) 
mupKpn:  
gaagatctcggtaccgatctcaatatgggactcccaaggc 
 
muPARre: 
atatagtttagcggccgcatcaggtccagaggagga 
 
mD1rev: 
gccctgagggaaagcacggccgccctgggaggctgggacacaggtagt 
 
mD1: 
tgtgtcccagcctcccagggcggccgtgctttccctcagggccgtta  
 
VN(1-66)u: 
cggggtaccatggcacccctgagaccccttctcatactggccctgctggcatgggttgc
tctggctgaccaagagtcatgcaagggc  
 
VN(1-66)d: 
ccg ctc gag gtt ttt ctc ctc 
 
FcU:  
ggctcgagcccaaatcttgtgacaaaact 
 
FcD: 
tatagcggccgctcatttacccggagacaggga 
 
 
Mouse uPAR mutant oligos (5’-3’) 
 
W32A mutant: 
FW : accgtgcttcgggaagcgcaagatgatagagag  
RV : ctctctatcatcttgcgcttcccgaagcacggt  
 
R58A mutant: 
FW: aggaccatgagttacgccatgggctccatgatc  
RV: gatcatggagcccatggcgtaactcatggtcct  
 
R58E mutant: 
FW: aggaccatgagttacgagatgggctccatgatc  
RV: gatcatggagcccatctcgtaactcatggtcct  
 
I63A mutant: 
FW: cgcatgggctccatggccatcagcctgacagag  
RV: ctctgtcaggctgatggccatggagcccatgcg  
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R92A mutant: 
FW: gctttccctcagggcgcttacctcgagtgtgcg 
RV: cgcacactcgaggtaagcgccctgagggaaagc 
 
A284Stop: 
FW: gggggcgccccctgttcagctgttacagccgct 
RV: agcggctgtaacagctgaacagggggcgccccc 
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